Standard BioTools (LAB) 10-Q 7 Aug 20 2020 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Annual Report	true
Document Period End Date	Jun. 30, 2020
Document Transition Report	false
Entity File Number	001-34180
Entity Registrant Name	FLUIDIGM CORP
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001162194
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0513190
Entity Address, Address Line One	2 Tower Place, Ste 2000
Entity Address, City or Town	South San Francisco,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	266-6000
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	FLDM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (shares)		71,316,370

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 42,965	$ 21,661
Short-term investments	2,431	36,978
Accounts receivable (net of allowances of $101 and $6, at June 30, 2020 and December 31, 2019, respectively)	9,983	18,981
Inventories	18,900	13,884
Prepaid expenses and other current assets	4,171	4,592
Total current assets	78,450	96,096
Property and equipment, net	7,865	8,056
Operating lease right-of-use asset, net	39,027	4,860
Other non-current assets	5,034	5,492
Developed technology, net	45,644	46,200
Goodwill	106,328	104,108
Total assets	282,348	264,812
Current liabilities:
Accounts payable	9,384	6,510
Accrued compensation and related benefits	6,757	5,160
Operating lease liabilities, current	2,170	1,833
Other accrued liabilities	5,758	7,515
Deferred revenue, current	14,279	11,803
Total current liabilities	38,348	32,821
Convertible notes, net	54,013	53,821
Deferred tax liability	9,655	11,494
Operating lease liabilities, non-current	39,139	4,323
Deferred revenue, non-current	7,936	8,168
Other non-current liabilities	538	573
Total liabilities	149,629	111,200
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized, no shares issued and outstanding at either June 30, 2020 or December 31, 2019	0	0
Common stock: $0.001 par value, 200,000 shares authorized at June 30, 2020 and December 31, 2019; 71,283 and 69,956 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	71	70
Additional paid-in capital	786,193	777,765
Accumulated other comprehensive loss	(809)	(582)
Accumulated deficit	(652,736)	(623,641)
Total stockholders’ equity	132,719	153,612
Total liabilities and stockholders’ equity	$ 282,348	$ 264,812

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 101	$ 6
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (shares)	10,000,000	10,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	200,000,000	200,000,000
Common stock, shares issued (shares)	71,283,000	69,956,000
Common stock, shares outstanding (shares)	71,283,000	69,956,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total revenue	$ 26,058	$ 28,196	$ 53,675	$ 58,307
Costs and expenses:
Research and development	8,448	7,865	17,147	16,237
Selling, general and administrative	20,616	22,134	43,311	44,958
Total costs and expenses	39,784	42,832	82,343	87,149
Loss from operations	(13,726)	(14,636)	(28,668)	(28,842)
Interest expense	(897)	(491)	(1,797)	(3,192)
Loss from extinguishment of debt	0	0	0	(9,000)
Other income (expense), net	463	231	(355)	715
Loss before income taxes	(14,160)	(14,896)	(30,820)	(40,319)
Income tax benefit	1,145	1,143	1,825	1,101
Net loss	$ (13,015)	$ (13,753)	$ (28,995)	$ (39,218)
Net loss per share, basic and diluted (usd per share)	$ (0.18)	$ (0.20)	$ (0.41)	$ (0.61)
Shares used in computing net loss per share, basic and diluted (shares)	70,916	69,158	70,691	63,923
Product revenue
Revenue:
Total revenue	$ 17,405	$ 23,235	$ 36,386	$ 48,062
Costs and expenses:
Cost of revenue	9,483	11,100	19,123	22,489
Service revenue
Revenue:
Total revenue	5,140	4,961	10,326	10,245
Costs and expenses:
Cost of revenue	1,237	1,733	2,762	3,465
Development revenue
Revenue:
Total revenue	3,000	0	3,000	0
Other revenue
Revenue:
Total revenue	$ 513	$ 0	$ 3,963	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (13,015)	$ (13,753)	$ (28,995)	$ (39,218)
Other comprehensive income (loss), net of tax
Foreign currency translation adjustment	109	(9)	(194)	(1)
Net change in unrealized gain (loss) on investments	(33)	63	(33)	65
Other comprehensive income (loss), net of tax	76	54	(227)	64
Comprehensive loss	$ (12,939)	$ (13,699)	$ (29,222)	$ (39,154)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment
Beginning Balance (shares) at Dec. 31, 2018			49,338,000
Beginning Balance at Dec. 31, 2018	$ 72,116		$ 49	$ 631,605	$ (687)	$ (558,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock on bond conversion (in shares)			19,460,000
Issuance of common stock on bond conversion	133,298		$ 19	133,279
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)			140,000
Issuance of restricted stock, net of shares withheld for taxes, and other	(176)		$ 1	(177)
Issuance of common stock from option exercises (in shares)			53,000
Issuance of common stock from option exercises	255			255
Stock-based compensation expense	2,207			2,207
Net loss	(25,465)					(25,465)
Other comprehensive income (loss)	10				10
Ending Balance (shares) at Mar. 31, 2019			68,991,000
Ending Balance at Mar. 31, 2019	182,245		$ 69	767,169	(677)	(584,316)
Beginning Balance (shares) at Dec. 31, 2018			49,338,000
Beginning Balance at Dec. 31, 2018	72,116		$ 49	631,605	(687)	(558,851)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(39,218)
Other comprehensive income (loss)	64
Ending Balance (shares) at Jun. 30, 2019			69,400,000
Ending Balance at Jun. 30, 2019	172,640		$ 69	771,263	(623)	(598,069)
Beginning Balance (shares) at Mar. 31, 2019			68,991,000
Beginning Balance at Mar. 31, 2019	182,245		$ 69	767,169	(677)	(584,316)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)			183,000
Issuance of restricted stock, net of shares withheld for taxes, and other	(325)			(325)
Issuance of common stock from option exercises (in shares)			130,000
Issuance of common stock from option exercises	793			793
Issuance of common stock under ESPP (in shares)			96,000
Issuance of common stock under ESPP	641			641
Stock-based compensation expense	2,985			2,985
Net loss	(13,753)					(13,753)
Other comprehensive income (loss)	54				54
Ending Balance (shares) at Jun. 30, 2019			69,400,000
Ending Balance at Jun. 30, 2019	$ 172,640		$ 69	771,263	(623)	(598,069)
Beginning Balance (shares) at Dec. 31, 2019	69,956,000		69,956,000
Beginning Balance at Dec. 31, 2019	$ 153,612	$ (100)	$ 70	777,765	(582)	(623,641)	$ (100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)			255,000
Issuance of restricted stock, net of shares withheld for taxes, and other	(146)			(146)
Stock-based compensation expense	2,364			2,364
Acquisition of InstruNor AS (shares)			485,000
Acquisition of InstruNor AS	2,049		$ 1	2,048
Net loss	(15,980)					(15,980)
Other comprehensive income (loss)	(303)				(303)
Ending Balance (shares) at Mar. 31, 2020			70,696,000
Ending Balance at Mar. 31, 2020	$ 141,496		$ 71	782,031	(885)	(639,721)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Beginning Balance (shares) at Dec. 31, 2019	69,956,000		69,956,000
Beginning Balance at Dec. 31, 2019	$ 153,612	$ (100)	$ 70	777,765	(582)	(623,641)	$ (100)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from option exercises (in shares)	0
Net loss	$ (28,995)
Other comprehensive income (loss)	$ (227)
Ending Balance (shares) at Jun. 30, 2020	71,283,000		71,283,000
Ending Balance at Jun. 30, 2020	$ 132,719		$ 71	786,193	(809)	(652,736)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Beginning Balance (shares) at Mar. 31, 2020			70,696,000
Beginning Balance at Mar. 31, 2020	$ 141,496		$ 71	782,031	(885)	(639,721)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)			286,000
Issuance of restricted stock, net of shares withheld for taxes, and other	(116)			(116)
Issuance of common stock under ESPP (in shares)			301,000
Issuance of common stock under ESPP	645			645
Stock-based compensation expense	3,633			3,633
Net loss	(13,015)					(13,015)
Other comprehensive income (loss)	$ 76				76
Ending Balance (shares) at Jun. 30, 2020	71,283,000		71,283,000
Ending Balance at Jun. 30, 2020	$ 132,719		$ 71	$ 786,193	$ (809)	$ (652,736)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities
Net loss	$ (28,995)	$ (39,218)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,016	2,351
Stock-based compensation expense	6,000	5,263
Amortization of developed technology	5,936	5,600
Amortization of debt discounts, premiums and issuance costs	275	2,037
Lease amortization	1,331	(250)
Loss on extinguishment of debt	0	9,000
Provision for excess and obsolete inventory	306	555
Loss on disposal of property and equipment	148	29
Other non-cash items	136	162
Changes in assets and liabilities:
Accounts receivable, net	9,055	(2,420)
Inventories	(4,892)	(2,041)
Prepaid expenses and other assets	(706)	(965)
Accounts payable	3,136	3,439
Deferred revenue	1,965	476
Other liabilities	(2,796)	(9,161)
Net cash used in operating activities	(7,085)	(25,143)
Investing activities
Acquisition, net of cash acquired	(5,154)	0
Purchases of investments	0	(44,614)
Proceeds from sale of investments	5,011	0
Proceeds from maturities of investments	29,400	0
Purchases of property and equipment	(1,671)	(685)
Net cash provided by (used in) investing activities	27,586	(45,299)
Financing activities
Payment of debt issuance cost	(375)	(15)
Proceeds from exercise of stock options	0	1,048
Proceeds from stock issuance from ESPP	645	641
Payments for taxes related to net share settlement of equity awards and other	(262)	(487)
Net cash provided by financing activities	8	1,187
Effect of foreign exchange rate fluctuations on cash and cash equivalents	(205)	(25)
Net increase (decrease) in cash, cash equivalents and restricted cash	20,304	(69,280)
Cash, cash equivalents and restricted cash at beginning of period	23,736	95,401
Cash, cash equivalents and restricted cash at end of period	44,040	26,121
Supplemental disclosures of cash flow information
Cash paid for interest	1,531	2,600
Cash paid for income taxes, net of refunds	194	139
Asset retirement obligations	$ 316	$ 319

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of BusinessFluidigm Corporation (the Company, Fluidigm, we, our or us) creates, manufactures, and markets technologies and tools for life sciences research, including preparatory and analytical instruments for Mass Cytometry, PCR, Library Prep, Single Cell Genomics, and consumables, including integrated fluidic circuits (IFC), assays, and reagents. Our focus is on the most pressing needs in translational and clinical research, including infectious disease, cancer, immunology and immunotherapy. We sell our instruments, consumables and services to academic institutions, clinical laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The Company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Consolidation The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of our wholly owned subsidiaries. As of June 30, 2020, we had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts in the condensed consolidated statements of income and condensed consolidated statements of cash flows were reclassified to conform with the current period presentation. These reclassifications were immaterial and did not affect prior period total assets, total liabilities, stockholders’ equity, total revenue, total costs and expenses, loss from operations or net loss. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. The full extent to which the COVID-19 pandemic impacts our business, results of operations and financial condition will depend on numerous evolving factors including, but not limited to, the magnitude and duration of the pandemic, the extent to which it will impact worldwide macroeconomic conditions, including the speed of recovery, and governmental and business reactions to the pandemic. We assessed certain accounting matters that generally require consideration of forecasted financial information in the context of information available to us and the unknown impact of COVID-19 as of June 30, 2020. These accounting matters included, but were not limited to, our allowance for doubtful accounts and credit losses, inventory and related reserves and the carrying value of goodwill and other long lived assets. Actual results could differ materially from these estimates and could have a material adverse effect on our consolidated financial statements. Foreign Currency Assets and liabilities of non-U.S. subsidiaries that use the local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity. Income and expense accounts are translated at monthly average exchange rates during the year. Revenue Recognition We generate revenue primarily from the sale of our products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. We also generate revenue from development agreements, license and royalty agreements and grants. Revenue is reported net of any sales, use and value-added taxes we collect from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue. We recognize revenue based on the amount of consideration we expect to receive in exchange for the goods and services we transfer to the customer. Our commercial arrangements typically include multiple distinct products and services, and we allocate revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices (SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, we estimate a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price. Product Revenue We recognize product revenue at the point in time when control of the goods passes to the customer and we have an enforceable right to payment. This generally occurs either when the product is shipped from one of our facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers generally do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment and generally become due in 30 to 60 days. We sometimes perform shipping and handling activities after control of the product passes to the customer. We have made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations. Service Revenue We recognize revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed. Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally one Development Revenue The Company has entered and may continue to enter into development agreements with third parties that provide for up-front and periodic milestone payments. Our development agreements may include more than one performance obligation. At the inception of the contract, we assess whether each obligation represents a separate performance obligation or whether such obligations should be combined as a single performance obligation. The transaction price for each development agreement is determined based on the amount of consideration we expect to be entitled to for satisfying all performance obligations within the agreement. We assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. In arrangements where we satisfy performance obligation(s) over time, we recognize development revenue typically using an input method based on our costs incurred relative to the total expected cost which determines the extent of our progress toward completion. As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the transaction price and progress towards completion. We review our estimate of the transaction price and progress toward completion based on the best information available to recognize the cumulative progress toward completion as of the end of each reporting period, and make revisions to such estimates as necessary. We may also generate revenue from development or collaboration agreements that do not include upfront or milestone-based payments and generally recognize revenue on these types of agreements based on the timing of development activities. Other Revenue Other revenue consists of license and royalty revenue, and grant revenue. We recognize revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In March 2020, we entered into an agreement to settle intellectual property infringement claims, in which we received a $3.5 million payment in exchange for a perpetual license under certain Fluidigm intellectual property. The settlement is considered a multiple-element arrangement with each element accounted for individually. Accordingly, $3.1 million of the proceeds was recognized as license revenue and $0.4 million was offset against legal costs. We receive grants from various entities to perform research and development activities over contractually defined periods. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory. Contract Costs Incremental sales commission costs incurred to obtain instrument service contracts are capitalized and amortized to selling, general and administrative expense over the life of the contract, which is generally one Product Warranties We generally provide a one-year warranty on our instruments. We accrue for estimated warranty obligations at the time of product shipment. We periodically review our warranty liability and record adjustments based on the terms of warranties provided to customers, and historical and anticipated warranty claim experience. This expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations. Significant Judgments Applying the revenue recognition practices discussed above often requires significant judgment. Judgment is required when identifying performance obligations, estimating SSP and allocating purchasing consideration in multi-element arrangements, determining the transaction price and progress towards completion on development arrangements and estimating the future amount of our warranty obligations. Moreover, significant judgment is required when interpreting commercial terms and determining when control of goods and services passes to the customer. Any material changes created by errors in judgment could have a material effect on our operating results and overall financial condition. Accounts Receivable Trade accounts receivable are recorded at net invoice value. We review our exposure to accounts receivable and provide allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. We evaluate such allowances on a regular basis and adjust them as needed. Concentrations of Business and Credit Risk Financial instruments that potentially subject us to credit risk consist of cash, cash equivalents, investments, and accounts receivable. Our cash, cash equivalents, and investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and investments are financial instruments that potentially subject us to concentrations of risk. Under our investment policy, we invest primarily in securities issued by the U.S. government. The goals of our investment policy, in order of priority, are as follows: preserve capital, meet liquidity needs, and optimize returns. We generally do not require collateral to support credit sales. To reduce credit risk, we perform credit evaluations of our customers. One customer from whom we derived development revenue exceeded 10% of revenue for the three months ended June 30, 2020. No other customer represented more than 10% of total revenue for three and six months ended June 30, 2020 or 2019. Including the development revenue, revenues from our five largest customers were 32% and 30% of total revenue for the three months ended June 30, 2020 and 2019, respectively. Revenues from our five largest customers were 23% and 20% of total revenue for the six months ended June 30, 2020 and 2019, respectively. There was no single customer that represented more than 10% of total accounts receivable at June 30, 2020, or December 31, 2019. Our products include components that are currently procured from a single source or a limited number of sources. We believe that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical limited-source components. Leases We determine if an arrangement is a lease, or contains a lease, at inception. Operating leases are included in operating lease right-of-use (ROU) assets and current and non-current operating lease liabilities in our condensed consolidated balance sheets. ROU assets represent our right-to-use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we generally use our incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Significant judgment is required in determining the incremental collateralized borrowing rate. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify, we will not recognize ROU assets or lease liabilities for leases with an initial lease term of one year or less. We also elected not to separate lease and nonlease components for our building leases. The nonlease components are generally variable in nature and are expected to represent most of our variable lease costs. Variable costs are expensed as incurred. We have taken a portfolio approach for our vehicle leases by country. Goodwill, Intangible Assets and Other Long-Lived Assets Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Our intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that we will be required to recognize an impairment charge include, but are not limited to, declines in our stock price or market capitalization, economic downturns and other macroeconomic events, including the current COVID-19 pandemic, declines in our market share or revenues, and an increase in our losses, rapid changes in technology, failure to achieve the benefits of capacity increases and utilization, significant litigation arising out of an acquisition, or other matters. Any impairment charges could have a material adverse effect on our operating results and net asset value in the quarter in which we recognize the impairment charge. In evaluating our goodwill and intangible assets with indefinite lives for indications of impairment, we first conduct an assessment of qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, we compare the fair value of our reporting unit to its carrying value. If the fair value of our reporting unit exceeds its carrying value, goodwill is not considered impaired and no further analysis is required. If the carrying value of the reporting unit exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill. We did not recognize any impairment of goodwill for any of the periods presented herein. We evaluate our long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, we estimate the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly. We did not recognize any impairment of intangibles for any of the periods presented herein. Convertible Notes In February 2014, we closed an underwritten public offering of $201.3 million aggregate principal amount of our 2.75% Senior Convertible Notes due 2034 (2014 Notes). In March 2018, we entered into separate privately negotiated transactions with certain holders of our 2014 Notes to exchange $150.0 million in aggregate principal amount of the 2014 Notes for our 2.75% Exchange Convertible Senior Notes due 2034 (2018 Notes). As the 2018 Notes were convertible, at our election, into cash, shares of our common stock, or a combination of cash and shares of our common stock, we accounted for the 2018 Notes under the cash conversion guidance in ASC 470, whereby the embedded conversion option in the 2018 Notes was separated and accounted for in equity. In the first quarter of 2019, the 2018 Notes were converted into 19.5 million shares of our common stock and the 2018 Notes were retired. We recorded a loss of $9.0 million on the retirement of the 2018 Notes. We determined the fair value of the 2018 Notes using valuation techniques that required us to make assumptions related to the implied discount rate. In November 2019, we closed a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of $55.0 million aggregate principal amount of our 5.25% Senior Convertible Notes due 2024 (2019 Notes). Most of the issuance proceeds were used to retire approximately $50.2 million of aggregate principal amount of our 2014 Notes, leaving approximately $1.1 million of aggregate principal amount of our 2014 Notes outstanding. As the 2019 Notes do not provide for a cash conversion feature, the 2019 Notes are recorded for as debt in their entirety in accordance with ASC 470. For the 2014, 2018 and 2019 Notes, offering-related costs, including underwriting costs, were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method. See Note 7 for a detailed discussion of the accounting treatment of the transactions and additional information. Comprehensive Loss Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on our investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss. The components of accumulated other comprehensive loss, net of tax, for the three and six months ended June 30, 2020 is as follows (in thousands): Foreign Currency Translation Adjustment Unrealized Gain (Loss) on Investments Accumulated Other Comprehensive Income (Loss) Ending balance at December 31, 2019 $ (618) $ 36 $ (582) Other comprehensive income (loss) (303) — (303) Ending balance at March 31, 2020 (921) 36 (885) Other comprehensive income (loss) 109 (33) 76 Ending balance at June 30, 2020 $ (812) $ 3 $ (809) Immaterial amounts of unrealized gains and losses have been reclassified into the condensed consolidated statement of operations for the three and six months ended June 30, 2020 and 2019. Net Loss per Share Our basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Restricted stock units, performance share units, and stock options to purchase our common stock are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented. The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands): Six Months Ended June 30, 2020 2019 Stock options, restricted stock units and performance awards 8,237 4,541 2019 Convertible Notes 18,966 — 2019 Convertible Notes potential make-whole shares 2,412 — 2014 Convertible Notes 19 916 Total 29,634 5,457 Recent Accounting Changes and Accounting Pronouncements Adoption of New Accounting Guidance In August 2018, the U.S.-based Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-15-Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), which establishes new guidance on the accounting for costs incurred to implement a cloud computing arrangement that is considered a service arrangement. The new guidance requires the capitalization of such costs, aligning it with the accounting for costs associated with developing or obtaining internal-use software. The new guidance is effective for fiscal years beginning after December 15, 2019. The adoption of the new guidance did not have a significant impact on our financial results. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The ASU eliminates the requirement for an entity to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, an entity performs its annual, or interim, goodwill impairment testing by comparing the fair value of a reporting unit with its carrying amount and recording an impairment charge for the amount by which the carrying amount exceeds the fair value. The ASU is effective for annual and interim goodwill impairment testing performed for our fiscal year beginning January 1, 2020. The adoption of the new guidance did not have a significant impact on our financial results. The FASB issued two ASUs related to financial instruments – credit losses. The ASUs issued were: (1) in June 2016, ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) Recent Accounting Pronouncements In November 2019, the FASB issued ASU 2019-12-Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this update improve consistent application of and simplify U.S. GAAP for Topic 740 by clarifying and amending existing guidance for, among other items, intra-period allocation, reporting tax law changes and losses in interim periods, state and local taxes not fully based on income and recognition of deferred tax liability related to certain transactions. There is also new guidance related to consolidated group reporting and tax impacts resulting from business combinations. The new guidance is effective for fiscal years beginning after December 15, 2020. We are currently evaluating the impact of adoption on our condensed consolidated financial statements.

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Business Combination	Business Combination On January 17, 2020, we completed the acquisition of all of the outstanding shares of InstruNor AS, a privately held Norwegian company (InstruNor). InstruNor is a provider of the only fully integrated sample preparation system for flow and mass cytometry. The acquisition of InstruNor supports our entry into the sample preparation market for cytometry analysis and expands our capabilities to include fully automated sample preparation for flow and mass cytometry. The value of this technology is reflected in the intangible asset for developed technology. The developed technology was valued using a discounted cash flow model for which the most sensitive assumption was revenue growth rate. The purchase price of $7.2 million included approximately $5.2 million in cash and 485,451 shares of our common stock valued at the closing price on the effective date of $4.22. A summary of the net cash flows is summarized below (in thousands): January 17, 2020 Cash consideration paid to former equity holders $ 5,165 Less: cash and cash equivalents acquired (11) Acquisition of InstruNor, net of cash acquired $ 5,154 The acquisition was accounted for in accordance with ASC 805, Business Combinations. The assets acquired and liabilities assumed were recorded at their estimated fair values at the InstruNor acquisition date. Goodwill of $2.2 million was calculated as the purchase price less the fair value of the net assets acquired as follows (in thousands): January 17, 2020 Purchase price: Cash consideration paid on closing to former equity holders $ 5,165 Non-cash consideration common shares 2,049 Total purchase price $ 7,214 Assets acquired: Cash and cash equivalents $ 11 Accounts receivable 32 Other receivables 13 Inventories, net 153 Developed technology 5,380 Liabilities assumed: Accounts payable 14 Other current liabilities 15 Deferred tax liability 566 Fair value of identifiable net assets acquired $ 4,994 Goodwill acquired on acquisition $ 2,220

Revenue

Revenue	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue The following table presents our revenue for the three and six months ended June 30, 2020 and 2019, respectively, based on geographic area and by source (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Geographic Markets: Americas $ 13,940 $ 11,120 $ 28,784 $ 24,091 EMEA 6,557 11,217 14,653 19,373 Asia-Pacific 5,561 5,859 10,238 14,843 Total revenue $ 26,058 $ 28,196 $ 53,675 $ 58,307 Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Source: Instruments $ 8,577 $ 12,201 $ 18,048 $ 25,041 Consumables 8,828 11,034 18,338 23,021 Product revenue 17,405 23,235 36,386 48,062 Service revenue 5,140 4,961 10,326 10,245 Development revenue 3,000 — 3,000 — Other revenue License and royalty revenue 63 — 3,163 — Grant revenue 450 — 800 — Total other revenue 513 — 3,963 — Total revenue $ 26,058 $ 28,196 $ 53,675 $ 58,307 Performance Obligations We reported $20.0 million of deferred revenue in our December 31, 2019 consolidated balance sheet. During the six months ended June 30, 2020, $6.2 million of the opening balance was recognized as revenue and $8.4 million of net additional advance payments were received from customers, primarily associated with instrument service contracts. At June 30, 2020, we reported $22.2 million of deferred revenue. The following table summarizes the expected timing of revenue recognition for unfulfilled performance obligations associated with instrument service contracts that were partially completed at June 30, 2020 (in thousands): Fiscal Year Expected Revenue (1) 2020 (remainder of the year) $ 7,401 2021 8,636 2022 4,702 Thereafter 3,164 Total $ 23,903 _______ (1) Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in our condensed consolidated financial statements and are subject to change if our customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins without penalty.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, net	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, net	Goodwill and Intangible Assets, net In connection with our acquisition of DVS Sciences, Inc. in February 2014, we recognized goodwill of $104.1 million and $112.0 million of developed technology. In the first quarter of 2020, we recognized $2.2 million of goodwill from the InstruNor acquisition and $5.4 million of developed technology (see Note 3). We are amortizing InstruNor developed technology over 8.0 years. Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Qualitative assessment includes assessing significant events and circumstances such as our current results, assumptions regarding future performance, strategic initiatives and overall economic factors, including the ongoing global COVID-19 pandemic and macroeconomic developments to determine the existence of potential indicators of impairment and assess if it is more likely than not that the fair value of our reporting unit or intangible assets is less than their carrying value. If indicators of impairment are identified, a quantitative impairment test is performed. During the first quarter of fiscal 2020, the Company assessed whether the current and potential future impact of the COVID-19 pandemic represented an event which necessitated an impairment review. This assessment included an update of the qualitative and quantitative factors affecting our business. As a result of this assessment, we determined that a triggering event had occurred and a quantitative impairment test was performed. As a result of this quantitative analysis, we determined that the fair values of our goodwill and developed technology intangibles were not less than their carrying values and no impairment was recognized. Intangible assets also include other patents and licenses, which are included in other non-current assets. Intangible assets, net, were as follows (in thousands): June 30, 2020 Gross Amount Accumulated Amortization Net Weighted-Average Amortization Period Developed technology $ 117,380 $ (71,736) $ 45,644 9.9 years Patents and licenses $ 11,274 $ (8,802) $ 2,472 7.8 years December 31, 2019 Gross Amount Accumulated Amortization Net Weighted-Average Amortization Period Developed technology $ 112,000 $ (65,800) $ 46,200 10.0 years Patents and licenses $ 11,274 $ (8,342) $ 2,932 7.8 years Total amortization expense for the three months ended June 30, 2020 and 2019 was $3.2 million and $3.1 million, respectively. Amortization of intangibles was $6.4 million and $6.2 million for the six months ended June 30, 2020 and 2019, respectively. Based on the carrying value of intangible assets, net, as of June 30, 2020, the amortization expense is expected to be as follows (in thousands): Fiscal Year Developed Technology Amortization Expense Patents and Licenses Amortization Expense Total 2020 (remainder of the year) $ 5,936 $ 457 $ 6,393 2021 11,873 759 12,632 2022 11,873 676 12,549 2023 11,873 570 12,443 2024 2,073 10 2,083 Thereafter 2,016 — 2,016 Total $ 45,644 $ 2,472 $ 48,116

Balance Sheet Details

Balance Sheet Details	6 Months Ended
	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details	Balance Sheet Details Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Cash and cash equivalents $ 42,965 $ 21,661 Restricted cash 1,075 2,075 Total cash, cash equivalents and restricted cash $ 44,040 $ 23,736 Short-term restricted cash of approximately $75 thousand is included in prepaid expenses and other current assets and $1.0 million of non-current restricted cash is included in other non-current assets in the condensed consolidated balance sheet as of June 30, 2020. Inventories Inventories consisted of the following as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Raw materials $ 9,665 $ 6,133 Work-in-process 1,063 659 Finished goods 8,172 7,092 Total inventories $ 18,900 $ 13,884 Property and Equipment, net Property and equipment consisted of the following as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Computer equipment and software $ 4,376 $ 3,997 Laboratory and manufacturing equipment 19,652 19,325 Leasehold improvements 7,962 7,788 Office furniture and fixtures 2,076 1,824 Property and equipment, gross 34,066 32,934 Less accumulated depreciation and amortization (26,309) (24,954) Construction-in-progress 108 76 Property and equipment, net $ 7,865 $ 8,056 Warranties Activity for our warranty accrual for the six months ended June 30, 2020 and 2019, which are included in other accrued liabilities, is summarized below (in thousands): Six Months Ended June 30, 2020 2019 Beginning balance $ 1,390 $ 863 Accrual for current period warranties 419 657 Warranty costs incurred (277) (429) Ending balance $ 1,532 $ 1,091

Convertible Notes and Credit Fa

Convertible Notes and Credit Facility	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Convertible Notes and Credit Facility	Convertible Notes and Credit Facility 2014 Senior Convertible Notes (2014 Notes) In February 2014, we closed an underwritten public offering of $201.3 million aggregate principal amount of our 2014 Notes. We received $195.2 million, net of underwriting discounts, from the issuance of the 2014 Notes and incurred approximately $1.1 million in offering-related expenses. The underwriting discount of $6.0 million and the debt issuance costs of $1.1 million were recorded as offsets to the proceeds. The underwriting discount and offering-related expenses are being amortized to interest expense using the effective-interest rate method. The effective interest rate on the 2014 Notes, reflecting the impact of debt discounts and issuance costs, is 3.0%. The 2014 Notes will mature on February 1, 2034, unless earlier converted, redeemed, or repurchased in accordance with the terms of the 2014 Notes. We have retired the majority of the 2014 Notes through the issuance of the 2018 Notes and 2019 Notes, as discussed below. As of June 30, 2020, there is $1.1 million aggregate principal of the 2014 Notes outstanding. 2018 Senior Convertible Notes (2018 Notes) In March 2018, we entered into separate privately negotiated transactions with certain holders of our 2014 Notes to exchange $150.0 million in aggregate principal amount of the 2014 Notes for 2018 Notes, leaving $51.3 million of the aggregate principal amount of 2014 Notes outstanding. As of the closing of the 2018 Notes on March 12, 2018, the estimated fair value was $145.5 million. The difference between the $150.0 million aggregate principal amount of the 2018 Notes and its fair value was being amortized over the expected term of the 2018 Notes using the effective interest method through the first note holder put date of February 6, 2023. The 2018 Notes accrued interest at a rate of 2.75% payable semi-annually in arrears on February 1 and August 1 of each year. The 2018 Notes were set to mature on February 1, 2034, unless earlier converted, redeemed, or repurchased in accordance with the terms of the indenture governing the 2018 Notes. The initial conversion rate of the 2018 Notes was 126.9438 shares of our common stock, par value $0.001 per share, per $1,000 principal amount of the 2018 Notes (which is equivalent to an initial conversion price of approximately $7.88 per share). The conversion rate was subject to adjustment upon the occurrence of certain specified events. Those certain specified events included holders who converted their 2018 Notes voluntarily prior to our exercise of the issuer’s conversion option described below or in connection with a make-whole fundamental change prior to February 6, 2023, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2018 Notes. Any time prior to the maturity of the 2018 Notes, we could convert the 2018 Notes, in whole but not in part, into cash, shares of our common stock, or combination thereof, if the closing price of our common stock equaled or exceeded 110% of the conversion price then in effect for a specified number of days. Offering-related costs for the 2018 Notes were approximately $2.8 million. Offering-related costs of $2.2 million were capitalized as debt issuance costs, recorded as an offset to the carrying value of the 2018 Notes, and were being amortized over the expected term of the 2018 Notes using the effective interest method through the first note holder put date of February 6, 2023. The effective interest rate on the 2018 Notes was 12.3%. Offering-related costs of $0.6 million were accounted for as equity issuance costs, recorded as an offset to additional paid-in capital, and were not subject to amortization. Offering-related costs were allocated between debt and equity in the same proportion as the allocation of the 2018 Notes between debt and equity. In the first quarter of 2019, we received notices from holders of the 2018 Notes electing to voluntarily convert approximately $138.1 million in aggregate principal amount of the 2018 Notes. In February 2019, we notified the trustee, U.S. Bank National Association, of our intention to exercise our issuer’s conversion option with respect to the remaining approximately $11.9 million in aggregate principal amount of 2018 Notes. In total, $150.0 million of the 2018 Notes were converted into 19.5 million shares of our common stock and the bonds were retired. We recognized a loss of $9.0 million on the retirement of the 2018 Notes, which represented the difference between the fair value of the bonds retired and their carrying costs. The net impact on equity was $133.3 million and represented the fair value of the bonds retired. 2019 Senior Convertible Notes (2019 Notes) In November 2019, we issued $55.0 million aggregate principal amount of 2019 Notes. Net proceeds of the offering of the 2019 Notes issuance were $52.7 million, after deductions for commissions and other debt issuance costs of approximately $2.3 million. $51.8 million of the proceeds of the 2019 Notes were used to retire $50.2 million aggregate principal amount of our 2014 Notes, leaving $1.1 million of aggregate principal value of 2014 Notes outstanding. We accounted for the transaction as an extinguishment of debt due to the significance of the change in value of the embedded conversion option, resulting in a $3.0 million loss in the fourth quarter of 2019. The loss on extinguishment of debt was calculated as the difference between the reacquisition price (i.e., the fair value of the principal amount of 2019 Notes) and the net carrying value of the 2014 Notes exchanged. The 2019 Notes bear interest at 5.25% per annum, payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2020. The Notes will mature on December 1, 2024, unless earlier repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the Notes is 344.8276 shares of the Company’s common stock per $1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $2.90 per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include voluntary conversion of the 2019 Notes prior to our exercise of the Issuer’s Conversion Option or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes will also be convertible at our option upon certain conditions in accordance with the terms of the indenture governing the 2019 Notes. On or after December 1, 2021 to December 1, 2022, if the price of the Company’s common stock has equaled or exceeded 150% of the Conversion Price then in effect for a specified number of days (Issuer’s Conversion Option), we may, at our option, elect to convert the 2019 Notes in whole but not in part into shares of the Company, determined in accordance with the terms of the indenture. On or after December 1, 2022, if the price of the Company’s common stock has equaled or exceeded 130% of the Conversion Price then in effect for a specified number of days, we may, at our option, elect to convert the 2019 Notes in whole but not in part into shares of the Company, determined in accordance with the terms of the indenture. Offering-related costs for the 2019 Notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes. The debt issuance costs are being amortized over the expected term of the 2019 Notes using the effective interest method through the maturity date of December 1, 2024. The effective interest rate on the 2019 Notes is 6.2%. The carrying values of the components of the 2014 Notes and the 2019 Notes are as follows (in thousands): June 30, 2020 December 31, 2019 2.75% 2014 Notes due 2034 Principal amount $ 1,079 $ 1,079 Unamortized debt discount (24) (18) Unamortized debt issuance cost (4) (4) $ 1,051 $ 1,057 5.25% 2019 Notes due 2024 Principal amount $ 55,000 $ 55,000 Unamortized debt issuance cost (2,038) (2,236) $ 52,962 $ 52,764 Net carrying value of all Notes $ 54,013 $ 53,821 2018 Revolving Credit Facility In August 2018, we entered into a revolving credit facility with Silicon Valley Bank (as amended, the Revolving Credit Facility) in an aggregate principal amount of up to the lesser of (i) $15.0 million (Maximum Amount) or (ii) the sum of (a) 85% of our eligible receivables and (b) 50% of our eligible inventory, in each case, subject to certain limitations (Borrowing Base), provided that the amount of eligible inventory that may be counted towards the Borrowing Base shall be subject to a cap as set forth in the Revolving Credit Facility. Subject to the level of this Borrowing Base, we may make and repay borrowings from time to time until the maturity of the Revolving Credit Facility. The Borrowing Base as of June 30, 2020 under the Revolving Credit Facility was $7.3 million. There were no borrowings outstanding under the Revolving Credit Facility at June 30, 2020. The Revolving Credit Facility is collateralized by substantially all our property, other than intellectual property. Until an amendment in April 2020, the Revolving Credit Facility was set to mature on August 2, 2020. The interest rate on outstanding loans under the Revolving Credit Facility was the greater of (i) prime rate plus 0.50% or (ii) 5.50%. Interest on any outstanding loans is due and payable monthly and the principal balance is due at maturity, though loans can be prepaid at any time without penalty. In addition, we pay a quarterly unused revolving line facility fee of 0.75% per annum on the average unused facility and an annual commitment fee of $112,500. Effective April 21, 2020, the Revolving Credit Facility was amended to extend the maturity date to August 2, 2022. In addition, the interest rate on outstanding loans under the Revolving Credit Facility was reduced by 0.25%. The quarterly unused line fee, which was previously based on the Maximum Amount, will now be based on the Borrowing Base. The annual commitment fee of $112,500 is unchanged. The Revolving Credit Facility contains customary affirmative and negative covenants that, unless waived by the bank, limit our ability to, among other things, incur additional indebtedness, grant liens, make investments, repurchase stock, pay dividends, transfer assets, enter into affiliate transactions, undergo a change of control, or engage in merger and acquisition activity, including merging or consolidating with a third party. The Revolving Credit Facility also contains customary events of default, subject to customary cure periods for certain defaults, that include, among other things, non-payment defaults, covenant defaults, material judgment defaults, bankruptcy and insolvency defaults, cross-defaults to certain other material indebtedness, and defaults due to inaccuracy of representation and warranties. Upon an event of default, the lender may declare all or a portion of the outstanding obligations payable by us to be immediately due and payable and exercise other rights and remedies provided for under the Revolving Credit Facility. During the existence of an event of default, interest on the obligations under the Revolving Credit Facility could be increased to 5.0% above the otherwise applicable rate of interest. We were in compliance with all the terms and conditions of the Revolving Credit Facility at June 30, 2020.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	Leases We have operating leases for buildings, equipment and vehicles. Existing leases have remaining terms of less than one year to ten years. Some leases contain options to extend the lease, usually for up to five years, and termination options. Supplemental balance sheet information related to leases was as follows as of June 30, 2020 and December 31, 2019 (in thousands, except for discount rate and lease term): June 30, 2020 December 31, 2019 Operating lease right-of-use buildings $ 40,618 $ 6,234 Operating lease right-of-use equipment 33 69 Operating lease right-of-use vehicles 452 355 Total operating lease right-of-use assets, gross 41,103 6,658 Accumulated amortization (2,076) (1,798) Total operating lease right-of-use assets, net $ 39,027 $ 4,860 Operating lease liabilities, current $ 2,170 $ 1,833 Operating lease liabilities, non-current 39,139 4,323 Total operating lease liabilities $ 41,309 $ 6,156 Weighted average remaining lease term (in years) 9.1 4.7 Weighted average discount rate per annum 11.9 % 5.0 % A new operating lease for our corporate headquarters in South San Francisco, California commenced in March 2020. We recorded a ROU asset of $35.7 million at the inception of the lease and an operating lease liability of $35.3 million. The lease term is approximately ten years. Future minimum lease payments over the life of the lease were discounted at a rate of 12.55%, which was our estimated incremental collateralized borrowing rate for the term of the lease at the inception of the lease. The following table presents the components of lease expense for the three and six months ended June 30, 2020 and 2019, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost (including variable costs) $ 2,312 $ 1,553 $ 4,511 $ 3,056 Variable costs including non-lease component $ 548 $ 703 $ 1,169 $ 1,303 Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of operating lease liabilities (included in net cash used in operating activities in thousands): Six Months Ended June 30, 2020 2019 Operating cash flows from operating leases $ 1,987 $ 2,061 Future minimum lease payments under commenced non-cancelable operating leases, which are as of June 30, 2020 as follows (in thousands): Fiscal Year Minimum Lease Payments for Operating Leases 2020 (remainder of year) $ 3,214 2021 7,282 2022 6,985 2023 6,907 2024 7,120 Thereafter 39,231 Total future minimum payments $ 70,739 Less: imputed interest (29,430) Total $ 41,309

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The following tables summarize our cash and available-for-sale securities that were measured at fair value by significant investment category within the fair value hierarchy (in thousands): June 30, 2020 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Fair Value Cash and Cash Equivalents Short-Term Marketable Securities Cash- Restricted Assets: Cash-unrestricted $ 20,196 $ — $ — $ 20,196 $ 20,196 $ — $ — Cash-restricted 1,075 — — 1,075 — — 1,075 Total cash $ 21,271 $ — $ — $ 21,271 $ 20,196 $ — $ 1,075 Available-for-sale: Level I: Money market funds $ 22,769 $ — $ — $ 22,769 $ 22,769 $ — $ — US treasury securities 2,428 3 — 2,431 — 2,431 — Subtotal $ 25,197 $ 3 $ — $ 25,200 $ 22,769 $ 2,431 $ — Total $ 46,468 $ 3 $ — $ 46,471 $ 42,965 $ 2,431 $ 1,075 December 31, 2019 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Fair Value Cash and Cash Equivalents Short-Term Marketable Securities Cash- Restricted Assets: Cash-unrestricted $ 16,614 $ — $ — $ 16,614 $ 16,614 $ — $ — Cash-restricted 2,075 — — 2,075 — — 2,075 Total cash $ 18,689 $ — $ — $ 18,689 $ 16,614 $ — $ 2,075 Available-for-sale: Level I: Money market funds $ 5,047 $ — $ — $ 5,047 $ 5,047 $ — $ — US treasury securities 36,942 36 — 36,978 — 36,978 — Subtotal $ 41,989 $ 36 $ — $ 42,025 $ 5,047 $ 36,978 $ — Total $ 60,678 $ 36 $ — $ 60,714 $ 21,661 $ 36,978 $ 2,075 There were no transfers between Level I and Level II measurements, and no changes in the valuation techniques used, during the six months ended June 30, 2020. Based on an evaluation of securities that were in a loss position, we did not recognize any other-than-temporary impairment charges for the six months ended June 30, 2020 and 2019. None of our investments have been in a continuous loss position for more than 12 months. We concluded that the declines in market value of our available-for-sale securities investment portfolio were temporary in nature and did not consider any of our investments to be other-than-temporarily impaired. Convertible Notes In 2019, we significantly reduced the amount of our outstanding debt. As a result, these securities are not traded frequently, so it is difficult to estimate a reliable and accurate market price and represent Level III valuations. A fair value for these assets cannot be determined by using readily observable inputs or measures, such as market prices or models. Fair values were estimated using pricing models and risk-adjusted value ranges. The following table summarizes the par value, carrying value and the estimated fair value of the 2014 and 2019 Notes at June 30, 2020 and December 31, 2019, respectively (in thousands): June 30, 2020 December 31, 2019 Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value 2014 Notes $ 1,079 $ 1,051 $ 1,122 $ 1,079 $ 1,057 $ 1,122 2019 Notes 55,000 52,962 82,369 55,000 52,764 73,975 Total $ 56,079 $ 54,013 $ 83,491 $ 56,079 $ 53,821 $ 75,097

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity InstruNor Acquisition In January 2020, we completed the acquisition of all of the outstanding shares of InstruNor (see Note 3). The purchase price was approximately $7.2 million, consisting of $5.2 million in cash and 485,451 shares of our common stock. Conversion of 2018 Notes In the first quarter of 2019, we issued 19,460,260 shares of our common stock in connection with the conversion of our 2018 Notes (see Note 7). As a result of this issuance of our common stock, we recorded a total of $133.3 million of equity, which was equivalent to the fair value of the bonds retired. At June 30, 2020, we had reserved shares of common stock for future issuance under equity compensation plans as follows: (in 000's) Securities To Be Issued Upon Exercise Of Options Securities To Be Issued Upon Release Of Restricted Stock and Performance Share Units Number Of Remaining Securities Available For Future Issuance 2009 Equity Incentive Plan 19 — — 2011 Equity Incentive Plan 1,609 6,138 2,823 DVS Sciences Inc. 2010 Equity Incentive Plan 23 — — 2017 Inducement Award Plan 207 241 — 2017 Employee Stock Purchase Plan — — 3,100 1,858 6,379 5,923

Stock-Based Plans

Stock-Based Plans	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Plans	Stock-Based Plans Our board of directors sets the terms, conditions, and restrictions related to our 2017 Employee Stock Purchase Plan (ESPP) and the grant of stock options, restricted stock units (RSUs) and performance-based awards under our equity incentive plans. Our board of directors determines the number of awards to grant and also sets vesting criteria. In general, RSUs vest on a quarterly basis over a period of four years from the date of grant at a rate of either 25% on the first anniversary of the grant date and ratably each quarter over the remaining 12 quarters, or ratably each quarter over 16 quarters, subject to the employees’ continued employment. In May 2020, we granted 1.8 million retention RSUs that vest over three years, with 50% of the RSUs vesting after one year and 25% of the RSUs vesting each year thereafter. Incentive stock options and non-statutory stock options granted under our 2011 Equity Incentive Plan (2011 Plan) have a term of no more than ten years from the date of grant and an exercise price of at least 100% of the fair market value of the underlying common stock on the date of grant. If a participant owns stock representing more than 10% of the voting power of all classes of our stock on the grant date, an incentive stock option awarded to the participant will have a term of no more than five years from the date of grant and an exercise price of at least 110% of the fair market value of the underlying common stock on the date of grant. Generally, options vest at a rate of either 25% on the first anniversary of the option grant date and ratably each month over the remaining period of 36 months, or ratably each month over 48 months. We may grant options with different vesting terms from time to time. For performance-based share awards, our board of directors sets the performance objectives and other vesting provisions in determining the number of shares or value of performance units and performance shares that will be paid out. Such payout will be a function of the extent to which performance objectives or other vesting provisions have been achieved. 2011 Equity Incentive Plan In January 2011, our board of directors adopted the 2011 Plan under which incentive stock options, non-statutory stock options, RSUs, stock appreciation rights, performance stock units (PSUs), and performance shares may be granted to our employees, directors, and consultants. In April 2019, our board of directors authorized, and in June 2019, our stockholders approved an amendment and restatement of the 2011 Plan to make various changes, including increasing the number of shares reserved for issuance by approximately 5.0 million shares and extending the term of the 2011 Plan until April 2029. In May 2020, our board of directors authorized, and in June 2020, our stockholders approved an increase in the number of shares reserved for issuance under the 2011 Plan of 1.4 million shares. 2009 Equity Incentive Plan and 2017 Inducement Award Plan Our 2009 Equity Incentive Plan (the 2009 Plan) terminated on the date the 2011 Plan was adopted. Options granted, or shares issued under the 2009 Plan that were outstanding on the date the 2011 Plan became effective, remained subject to the terms of the 2009 Plan. In January 2017, we adopted the Fluidigm Corporation 2017 Inducement Award Plan (Inducement Plan) and reserved 2 million shares of our common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan provided for the grant of equity-based awards on terms substantially similar to the 2011 Plan. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under the Inducement Plan were only be made to individuals not previously our employees or non-employee members of our board of directors (or following such individual’s bona fide period of non-employment), as an inducement material to the individual’s entry into employment with us or in connection with a merger or acquisition, to the extent permitted by Rule 5635(c)(3) of the Nasdaq Listing Rules. In June 2019, concurrently with the increase in shares available for grant under the 2011 Plan, the Inducement Plan was terminated such that no further grants could be made thereunder. Options granted and shares issued under the Inducement Plan that were outstanding when the Inducement Plan was terminated remain outstanding subject to their terms and the terms of the Inducement Plan. Valuation and Expense Information We use the Black-Scholes option-pricing model to estimate the fair value of stock options granted under our equity incentive plans. We grant stock options at exercise prices not less than the fair value of our common stock at the date of grant. The fair value of RSUs granted to employees was estimated on the date of grant by multiplying the number of shares granted by the fair market value of our common stock on the grant date. Activity under the 2011 Plan, the 2009 Plan, and the Inducement Plan was as follows: Restricted Stock Units : Number of Units (in 000s) Weighted-Average Balance at December 31, 2019 2,551 $ 7.43 RSU granted 3,642 $ 3.95 RSU released (602) $ 7.72 RSU forfeited (222) $ 6.82 Balance as of June 30, 2020 5,369 $ 5.06 As of June 30, 2020, the unrecognized compensation costs related to outstanding unvested RSUs under our equity incentive plans were $24.8 million. We expect to recognize those costs over a weighted average period of 3.0 years. Stock Options : Number of Weighted-Average Weighted- Aggregate Intrinsic Value (1) in (000s) Balance at December 31, 2019 2,027 $ 7.78 6.8 $ 81 Options granted 105 $ 3.74 Options exercised — $ — Options forfeited (274) $ 5.71 Balance as of June 30, 2020 1,858 $ 7.86 6.1 $ 163 Vested at June 30, 2020 1,372 $ 8.69 5.4 $ 115 Awards expected to vest at June 30, 2020 474 $ 5.50 8.1 $ 48 (1) Aggregate intrinsic value as of June 30, 2020 was calculated as the difference between the closing price per share of our common stock on the last trading day of June 30, 2020, which was $4.01, and the exercise price of the options, multiplied by the number of in-the-money options. As of June 30, 2020, the unrecognized compensation costs related to outstanding unvested options under our equity incentive plans were $1.4 million. We expect to recognize those costs over a weighted average period of 1.5 years. Performance-based Awards Performance Stock Units with Market Conditions We have granted PSU awards to certain executive officers and senior level employees. The number of PSUs ultimately earned under these awards is calculated based on the Total Shareholder Return (TSR) of our common stock as compared to the TSR of a defined group of peer companies during the applicable three-year performance period. The percentage of PSUs that vest will depend on our relative position at the end of the performance period and can range from 0% to 200% of the number of units granted. Under FASB ASC Topic 718, the provisions of the PSU awards related to TSR are considered a market condition, and the effects of that market condition are reflected in the grant date fair value of the awards. We used a Monte Carlo simulation pricing model to incorporate the market condition effects at our grant date. Activity under the TSR-based PSUs is as follows: Number of Units (in 000s) Weighted-Average Balance at December 31, 2019 547 $ 15.09 PSU granted 509 $ 4.82 PSU released — $ — PSU forfeited (94) $ 14.26 Balance at June 30, 2020 962 $ 9.74 As of June 30, 2020, the unrecognized compensation costs related to these awards were $5.7 million. We expect to recognize those costs over a weighted average period of 2.0 years. Performance Stock Units with Performance Conditions During 2019, we also granted a PSU award under which the number of PSUs that ultimately vest is dependent on achieving certain discrete operational milestones between September 30, 2019 and December 31, 2020. Activity to date under this PSU award is as follows: Number of Units (in 000s) Weighted-Average Balance at December 31, 2019 64 $ 7.05 PSU granted — $ — PSU released (4) $ 7.05 PSU forfeited (12) $ 7.05 Balance at June 30, 2020 48 $ 7.05 2017 Employee Stock Purchase Plan In August 2017, our stockholders approved our ESPP at the annual meeting of stockholders. Our ESPP offers U.S. and some non-U.S. employees the right to purchase shares of our common stock. Our first ESPP offering period began on October 1, 2017 with a shorter offering period ending on November 30, 2017. Prior to June 2019, our ESPP program had a six-month offering period, with a new period commencing on the first trading day on or after May 31 and November 30 of each year. Employees were eligible to participate through payroll deductions of up to 10% of their compensation. The purchase price at which shares were sold under the ESPP was 85% of the lower of the fair market value of a share of our common stock on the first day of the offering period or the last day of the offering period. Effective in June 2019, our ESPP program was amended to offer a twelve-month offering period with two six-month purchase periods beginning on each of May 31 and November 30. Employees were eligible under the amended program to participate through payroll deductions of up to 15% of their compensation. Employees may not purchase more than $25 thousand of stock for any calendar year. Under the updated ESPP program, the purchase price at which shares are sold for the first purchase period is 85% of the lower of the fair market value of a share of our common stock on the first day of the offering period or the last day of the first purchase period. For the second purchase period, the purchase price at which shares are sold is 85% of the lower of the fair market value of the common stock on the first day of the offering period and the last day of the offering period. In the event the fair market value of the common stock at the beginning of the second purchase period is less than the fair market value on the beginning of the offering period, the purchase price for the second offering period is reset to 85% of the lower of the fair value of the common stock at the beginning of the second purchase period and the last day of the offering period. The offering period of June 1, 2019 to May 31, 2020 had two purchase periods, with one period ending November 30, 2019 and the other period ending May 31, 2020. As the fair market value of the common stock at November 30, 2019 was lower than the fair value of the common stock at the beginning of the offering period, the purchase price for the second purchase period was reset based on the lower of the November 30, 2019 price and the May 31, 2020 price. The resetting of the purchase price is considered to be a modification of the original terms of the award. Under ASC 718, the incremental fair value based on the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified was approximately $0.3 million. This amount was amortized over the remaining offering period which ended May 31, 2020. In April 2020, our board of directors authorized, and in June 2020, our stockholders approved, an amendment and restatement of the ESPP that increased the number of shares reserved for issuance by an additional 3.0 million shares and made various other changes. Effective June 2020, our ESPP program was amended to offer a six-month offering period, with a new offering and purchase period commencing on the first trading day on or after May 31 and November 30 of each year. Employees are eligible under the amended program to participate through payroll deductions of up to 10% of their compensation. Employees may not purchase more than $25 thousand of stock for any calendar year. The purchase price of the shares sold under the ESPP is 85% of the lower of fair market value of a share of our common stock on the first day of the offering period or the last day of the offering period. Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Restricted Stock Units, Stock Options and Performance Share Units $ 3,331 $ 2,848 $ 5,443 $ 4,993 Employee Stock Purchase Plan 303 144 557 270 Total Share-based Compensation $ 3,634 $ 2,992 $ 6,000 $ 5,263

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our quarterly provision for income taxes is based on an estimated effective annual income tax rate. Our quarterly provision for income taxes also includes the tax impact of certain unusual or infrequently occurring items, if any, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, in the interim period in which they occur. We recorded a tax benefit of $1.1 million for both the three months ended June 30, 2020 and 2019. We recorded a tax benefit of $1.8 million and $1.1 million for the six months ended June 30, 2020 and 2019, respectively. The benefits for all periods were primarily attributable to the tax benefit from the amortization of our acquisition-related deferred tax liabilities partially offset by tax provisions for our foreign operations and state minimum income taxes. Our tax benefit for income taxes for the periods presented differ from the 21% U.S. Federal statutory rate for the six months ended June 30, 2020 and 2019, respectively, primarily due to maintaining a valuation allowance for most of our deferred tax assets, which primarily consist of net operating loss carryforwards. Our tax positions are subject to audits by multiple tax jurisdictions. We believe that we have provided adequate reserves for uncertain tax positions for all tax years still open for assessment. For the three and six months ended June 30, 2020, and 2019, respectively, we did not recognize any material interest or penalties related to uncertain tax positions. Recording deferred tax assets is appropriate when realization of these assets is more likely than not. Assessing the realizability of deferred tax assets is dependent upon several factors including historical financial results. The deferred tax assets have been offset by valuation allowances. In the future we may release valuation allowances and recognize deferred tax assets in certain of our foreign subsidiaries depending on the achievement of future profitability in the relevant jurisdictions. Any release of valuation allowances could have the effect of decreasing the income tax provision in the period the valuation allowance is released. We continue to monitor the likelihood that we will be able to recover our deferred tax assets, including those for which a valuation allowance is recorded. There can be no assurance that we will generate profits in the future periods enabling us to fully realize our deferred tax assets. The timing of recording a valuation allowance or the reversal of such valuation allowance is subject to objective and subjective factors that cannot be readily predicted in advance. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was signed into law. The CARES Act includes provisions relating to refundable payroll tax credits, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to the tax deprecation methods for qualified improvement property. We are currently analyzing the impact of these changes and therefore, an estimate of the impact on income taxes, if any, is not yet available.

Information About Geographic Ar

Information About Geographic Areas	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Information About Geographic Areas	Information About Geographic Areas We operate in one reporting segment that develops, manufacturers and commercializes tools for life sciences research. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. For purposes of allocating resources and evaluating regional financial performance, our chief executive officer reviews separate sales information for the different regions of the world. Our general and administrative expenses and our research and development expenses are not allocated to any specific region. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States. A summary table of our total revenue by geographic areas of our customers and by product and services for the three and six months ended June 30, 2020 and 2019 is included in Note 4 to the condensed consolidated financial statements. Sales to customers in the United States represented $13.4 million, or 51% of total revenues, and $27.5 million, or 51% of total revenues, for the three and six months ended June 30, 2020, respectively. Sales to customers in the United States represented $9.9 million, or 35% of total revenues, and $22.4 million, or 38% of total revenues, for the three and six months ended June 30, 2019, respectively. No foreign country or jurisdiction had sales in excess of 10% of total revenues for the three months ended June 30, 2020 and 2019, except for China, which had sales of $3.5 million, or 13% of total revenues, and $4.0 million, or 14% of total revenues, respectively. There was no foreign country or jurisdiction with sales in excess of 10% of our total revenues for the six months ended June 30, 2020 or 2019, except for China, which had sales of $7.5 million, or 13% of total revenues, for the six months ended June 30, 2019.

Development Agreement

Development Agreement	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Development Agreement	Development Agreement Effective March 31, 2020, we signed an OEM Supply and Development Agreement (Development Agreement) with a customer. Under the Development Agreement, Fluidigm will develop products based on our microfluidics technology. The Development Agreement provides up-front and periodic milestone payments of up to $11.7 million during the development stage. The development stage is expected to last approximately one year from the date of the agreement. We recognized $3.0 million of development revenue from this agreement in the three and six months ended June 30, 2020, along with approximately $1.0 million of deferred revenue.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification From time to time, we have entered into indemnification provisions under certain of our agreements in the ordinary course of business, typically with business partners, customers, and suppliers. Pursuant to these agreements, we may indemnify, hold harmless, and agree to reimburse the indemnified parties on a case-by-case basis for losses suffered or incurred by the indemnified parties in connection with any patent or other intellectual property infringement claim by any third party with respect to our products. The term of these indemnification provisions is generally perpetual from the time of the execution of the agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is typically not limited to a specific amount. In addition, we have entered into indemnification agreements with our officers, directors, and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. Contingencies

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsIn July 20, 2020, we entered into a letter contract with the National Institutes of Health (NIH) for a project under the NIH Rapid Acceleration of Diagnostics (RADx) program. The RADx program aims to support a range of new lab-based and point-of-care tests that could significantly increase the number, type and availability of COVID-19 tests. This project, with a total proposed budget of up to $37.0 million, contemplates expanding production capacity and throughput capabilities for COVID-19 testing with Fluidigm microfluidics technology. The letter contract provides Fluidigm with access to up to $12.2 million of initial funding based on completion and delivery of certain validation milestones prior to execution of a definitive contract.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and include the accounts of our wholly owned subsidiaries. As of June 30, 2020, we had wholly owned subsidiaries in Singapore, Canada, the Netherlands, Japan, France, the United Kingdom, China, Germany and Norway. All subsidiaries, except for Singapore, use their local currency as their functional currency. The Singapore subsidiary uses the U.S. dollar as its functional currency. All intercompany transactions and balances have been eliminated in consolidation.
Reclassifications	Certain prior period amounts in the condensed consolidated statements of income and condensed consolidated statements of cash flows were reclassified to conform with the current period presentation. These reclassifications were immaterial and did not affect prior period total assets, total liabilities, stockholders’ equity, total revenue, total costs and expenses, loss from operations or net loss.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. The full extent to which the COVID-19 pandemic impacts our business, results of operations and financial condition will depend on numerous evolving factors including, but not limited to, the magnitude and duration of the pandemic, the extent to which it will impact worldwide macroeconomic conditions, including the speed of recovery, and governmental and business reactions to the pandemic. We assessed certain accounting matters that generally require consideration of forecasted financial information in the context of information available to us and the unknown impact of COVID-19 as of June 30, 2020. These accounting matters included, but were not limited to, our allowance for doubtful accounts and credit losses, inventory and related reserves and the carrying value of goodwill and other long lived assets. Actual results could differ materially from these estimates and could have a material adverse effect on our consolidated financial statements.
Foreign Currency	Foreign CurrencyAssets and liabilities of non-U.S. subsidiaries that use the local currency as their functional currency are translated into U.S. dollars at exchange rates in effect on the balance sheet date. The adjustments resulting from the foreign currency translations are recorded in accumulated other comprehensive loss, a separate component of stockholders’ equity. Income and expense accounts are translated at monthly average exchange rates during the year.
Revenue Recognition	Revenue Recognition We generate revenue primarily from the sale of our products and services. Product revenue is derived from the sale of instruments and consumables, including IFCs, assays and reagents. Service revenue is derived from the sale of instrument service contracts, repairs, installation, training and other specialized product support services. We also generate revenue from development agreements, license and royalty agreements and grants. Revenue is reported net of any sales, use and value-added taxes we collect from customers as required by government authorities. Research and development cost includes costs associated with development and grant revenue. We recognize revenue based on the amount of consideration we expect to receive in exchange for the goods and services we transfer to the customer. Our commercial arrangements typically include multiple distinct products and services, and we allocate revenue to these performance obligations based on their relative standalone selling prices. Standalone selling prices (SSP) are generally determined using observable data from recent transactions. In cases where sufficient data is not available, we estimate a product’s SSP using a cost plus a margin approach or by applying a discount to the product’s list price. Product Revenue We recognize product revenue at the point in time when control of the goods passes to the customer and we have an enforceable right to payment. This generally occurs either when the product is shipped from one of our facilities or when it arrives at the customer’s facility, based on the contractual terms. Customers generally do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment and generally become due in 30 to 60 days. We sometimes perform shipping and handling activities after control of the product passes to the customer. We have made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations. Service Revenue We recognize revenue from repairs, maintenance, installation, training and other specialized product support services at the point in time the work is completed. Installation and training services are generally billed in advance of service. Repairs and other services are generally billed at the point the work is completed. Revenue associated with instrument service contracts is recognized on a straight-line basis over the life of the agreement, which is generally one Development Revenue The Company has entered and may continue to enter into development agreements with third parties that provide for up-front and periodic milestone payments. Our development agreements may include more than one performance obligation. At the inception of the contract, we assess whether each obligation represents a separate performance obligation or whether such obligations should be combined as a single performance obligation. The transaction price for each development agreement is determined based on the amount of consideration we expect to be entitled to for satisfying all performance obligations within the agreement. We assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. In arrangements where we satisfy performance obligation(s) over time, we recognize development revenue typically using an input method based on our costs incurred relative to the total expected cost which determines the extent of our progress toward completion. As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the transaction price and progress towards completion. We review our estimate of the transaction price and progress toward completion based on the best information available to recognize the cumulative progress toward completion as of the end of each reporting period, and make revisions to such estimates as necessary. We may also generate revenue from development or collaboration agreements that do not include upfront or milestone-based payments and generally recognize revenue on these types of agreements based on the timing of development activities. Other Revenue Other revenue consists of license and royalty revenue, and grant revenue. We recognize revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. In March 2020, we entered into an agreement to settle intellectual property infringement claims, in which we received a $3.5 million payment in exchange for a perpetual license under certain Fluidigm intellectual property. The settlement is considered a multiple-element arrangement with each element accounted for individually. Accordingly, $3.1 million of the proceeds was recognized as license revenue and $0.4 million was offset against legal costs. We receive grants from various entities to perform research and development activities over contractually defined periods. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory. Contract Costs Incremental sales commission costs incurred to obtain instrument service contracts are capitalized and amortized to selling, general and administrative expense over the life of the contract, which is generally one Product Warranties We generally provide a one-year warranty on our instruments. We accrue for estimated warranty obligations at the time of product shipment. We periodically review our warranty liability and record adjustments based on the terms of warranties provided to customers, and historical and anticipated warranty claim experience. This expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations. Significant Judgments Applying the revenue recognition practices discussed above often requires significant judgment. Judgment is required when identifying performance obligations, estimating SSP and allocating purchasing consideration in multi-element arrangements, determining the transaction price and progress towards completion on development arrangements and estimating the future amount of our warranty obligations. Moreover, significant judgment is required when interpreting commercial terms and determining when control of goods and services passes to the customer. Any material changes created by errors in judgment could have a material effect on our operating results and overall financial condition.
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded at net invoice value. We review our exposure to accounts receivable and provide allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. We evaluate such allowances on a regular basis and adjust them as needed.
Concentrations of Business and Credit Risk	Concentrations of Business and Credit Risk Financial instruments that potentially subject us to credit risk consist of cash, cash equivalents, investments, and accounts receivable. Our cash, cash equivalents, and investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and investments are financial instruments that potentially subject us to concentrations of risk. Under our investment policy, we invest primarily in securities issued by the U.S. government. The goals of our investment policy, in order of priority, are as follows: preserve capital, meet liquidity needs, and optimize returns. We generally do not require collateral to support credit sales. To reduce credit risk, we perform credit evaluations of our customers. One customer from whom we derived development revenue exceeded 10% of revenue for the three months ended June 30, 2020. No other customer represented more than 10% of total revenue for three and six months ended June 30, 2020 or 2019. Including the development revenue, revenues from our five largest customers were 32% and 30% of total revenue for the three months ended June 30, 2020 and 2019, respectively. Revenues from our five largest customers were 23% and 20% of total revenue for the six months ended June 30, 2020 and 2019, respectively. There was no single customer that represented more than 10% of total accounts receivable at June 30, 2020, or December 31, 2019.
Leases	Leases We determine if an arrangement is a lease, or contains a lease, at inception. Operating leases are included in operating lease right-of-use (ROU) assets and current and non-current operating lease liabilities in our condensed consolidated balance sheets. ROU assets represent our right-to-use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we generally use our incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Significant judgment is required in determining the incremental collateralized borrowing rate. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Goodwill, Intangible Assets and Other Long-Lived Assets	Goodwill, Intangible Assets and Other Long-Lived Assets Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Our intangible assets include developed technology, patents and licenses. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets’ respective estimated useful lives. Goodwill and intangible assets with indefinite lives are not subject to amortization but are tested for impairment on an annual basis during the fourth quarter or whenever events or changes in circumstances indicate the carrying amount of these assets may not be recoverable. Events or changes in circumstances that could affect the likelihood that we will be required to recognize an impairment charge include, but are not limited to, declines in our stock price or market capitalization, economic downturns and other macroeconomic events, including the current COVID-19 pandemic, declines in our market share or revenues, and an increase in our losses, rapid changes in technology, failure to achieve the benefits of capacity increases and utilization, significant litigation arising out of an acquisition, or other matters. Any impairment charges could have a material adverse effect on our operating results and net asset value in the quarter in which we recognize the impairment charge. In evaluating our goodwill and intangible assets with indefinite lives for indications of impairment, we first conduct an assessment of qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, we compare the fair value of our reporting unit to its carrying value. If the fair value of our reporting unit exceeds its carrying value, goodwill is not considered impaired and no further analysis is required. If the carrying value of the reporting unit exceeds its fair value, then an impairment loss equal to the difference would be recorded to goodwill. We did not recognize any impairment of goodwill for any of the periods presented herein. We evaluate our long-lived assets, including finite-lived intangibles, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If any indicator of impairment exists, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of the asset can be recovered through undiscounted future operating cash flows. If impairment is indicated, we estimate the asset’s fair value using future discounted cash flows associated with the use of the asset and adjust the carrying value of the asset accordingly. We did not recognize any impairment of intangibles for any of the periods presented herein.
Convertible Notes	Convertible Notes In February 2014, we closed an underwritten public offering of $201.3 million aggregate principal amount of our 2.75% Senior Convertible Notes due 2034 (2014 Notes). In March 2018, we entered into separate privately negotiated transactions with certain holders of our 2014 Notes to exchange $150.0 million in aggregate principal amount of the 2014 Notes for our 2.75% Exchange Convertible Senior Notes due 2034 (2018 Notes). As the 2018 Notes were convertible, at our election, into cash, shares of our common stock, or a combination of cash and shares of our common stock, we accounted for the 2018 Notes under the cash conversion guidance in ASC 470, whereby the embedded conversion option in the 2018 Notes was separated and accounted for in equity. In the first quarter of 2019, the 2018 Notes were converted into 19.5 million shares of our common stock and the 2018 Notes were retired. We recorded a loss of $9.0 million on the retirement of the 2018 Notes. We determined the fair value of the 2018 Notes using valuation techniques that required us to make assumptions related to the implied discount rate. In November 2019, we closed a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of $55.0 million aggregate principal amount of our 5.25% Senior Convertible Notes due 2024 (2019 Notes). Most of the issuance proceeds were used to retire approximately $50.2 million of aggregate principal amount of our 2014 Notes, leaving approximately $1.1 million of aggregate principal amount of our 2014 Notes outstanding. As the 2019 Notes do not provide for a cash conversion feature, the 2019 Notes are recorded for as debt in their entirety in accordance with ASC 470. For the 2014, 2018 and 2019 Notes, offering-related costs, including underwriting costs, were capitalized as debt issuance costs, recorded as an offset to the carrying value of the related Notes, and are amortized over the expected term of the related Notes using the effective interest method.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on our investments and foreign currency translation adjustments. Total comprehensive loss for all periods presented has been disclosed in the condensed consolidated statements of comprehensive loss.
Net Loss per Share	Net Loss per Share Our basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Restricted stock units, performance share units, and stock options to purchase our common stock are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.
Recent Accounting Changes and Accounting Pronouncements	Recent Accounting Changes and Accounting Pronouncements Adoption of New Accounting Guidance In August 2018, the U.S.-based Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-15-Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), which establishes new guidance on the accounting for costs incurred to implement a cloud computing arrangement that is considered a service arrangement. The new guidance requires the capitalization of such costs, aligning it with the accounting for costs associated with developing or obtaining internal-use software. The new guidance is effective for fiscal years beginning after December 15, 2019. The adoption of the new guidance did not have a significant impact on our financial results. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The ASU eliminates the requirement for an entity to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, an entity performs its annual, or interim, goodwill impairment testing by comparing the fair value of a reporting unit with its carrying amount and recording an impairment charge for the amount by which the carrying amount exceeds the fair value. The ASU is effective for annual and interim goodwill impairment testing performed for our fiscal year beginning January 1, 2020. The adoption of the new guidance did not have a significant impact on our financial results. The FASB issued two ASUs related to financial instruments – credit losses. The ASUs issued were: (1) in June 2016, ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) Recent Accounting Pronouncements In November 2019, the FASB issued ASU 2019-12-Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this update improve consistent application of and simplify U.S. GAAP for Topic 740 by clarifying and amending existing guidance for, among other items, intra-period allocation, reporting tax law changes and losses in interim periods, state and local taxes not fully based on income and recognition of deferred tax liability related to certain transactions. There is also new guidance related to consolidated group reporting and tax impacts resulting from business combinations. The new guidance is effective for fiscal years beginning after December 15, 2020. We are currently evaluating the impact of adoption on our condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Components of accumulated other comprehensive loss	The components of accumulated other comprehensive loss, net of tax, for the three and six months ended June 30, 2020 is as follows (in thousands): Foreign Currency Translation Adjustment Unrealized Gain (Loss) on Investments Accumulated Other Comprehensive Income (Loss) Ending balance at December 31, 2019 $ (618) $ 36 $ (582) Other comprehensive income (loss) (303) — (303) Ending balance at March 31, 2020 (921) 36 (885) Other comprehensive income (loss) 109 (33) 76 Ending balance at June 30, 2020 $ (812) $ 3 $ (809)
Summary of potential common shares excluded from computations of net loss per share attributed to common stockholders	The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands): Six Months Ended June 30, 2020 2019 Stock options, restricted stock units and performance awards 8,237 4,541 2019 Convertible Notes 18,966 — 2019 Convertible Notes potential make-whole shares 2,412 — 2014 Convertible Notes 19 916 Total 29,634 5,457

Business Combination (Tables)

Business Combination (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Schedule of consideration transferred	A summary of the net cash flows is summarized below (in thousands): January 17, 2020 Cash consideration paid to former equity holders $ 5,165 Less: cash and cash equivalents acquired (11) Acquisition of InstruNor, net of cash acquired $ 5,154
Schedule of consideration transferred and assets acquired and liabilities assumed	Goodwill of $2.2 million was calculated as the purchase price less the fair value of the net assets acquired as follows (in thousands): January 17, 2020 Purchase price: Cash consideration paid on closing to former equity holders $ 5,165 Non-cash consideration common shares 2,049 Total purchase price $ 7,214 Assets acquired: Cash and cash equivalents $ 11 Accounts receivable 32 Other receivables 13 Inventories, net 153 Developed technology 5,380 Liabilities assumed: Accounts payable 14 Other current liabilities 15 Deferred tax liability 566 Fair value of identifiable net assets acquired $ 4,994 Goodwill acquired on acquisition $ 2,220

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Summary of disaggregation of revenue	The following table presents our revenue for the three and six months ended June 30, 2020 and 2019, respectively, based on geographic area and by source (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Geographic Markets: Americas $ 13,940 $ 11,120 $ 28,784 $ 24,091 EMEA 6,557 11,217 14,653 19,373 Asia-Pacific 5,561 5,859 10,238 14,843 Total revenue $ 26,058 $ 28,196 $ 53,675 $ 58,307 Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Source: Instruments $ 8,577 $ 12,201 $ 18,048 $ 25,041 Consumables 8,828 11,034 18,338 23,021 Product revenue 17,405 23,235 36,386 48,062 Service revenue 5,140 4,961 10,326 10,245 Development revenue 3,000 — 3,000 — Other revenue License and royalty revenue 63 — 3,163 — Grant revenue 450 — 800 — Total other revenue 513 — 3,963 — Total revenue $ 26,058 $ 28,196 $ 53,675 $ 58,307
Summary of expected timing of revenue recognition	The following table summarizes the expected timing of revenue recognition for unfulfilled performance obligations associated with instrument service contracts that were partially completed at June 30, 2020 (in thousands): Fiscal Year Expected Revenue (1) 2020 (remainder of the year) $ 7,401 2021 8,636 2022 4,702 Thereafter 3,164 Total $ 23,903 _______ (1) Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in our condensed consolidated financial statements and are subject to change if our customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins without penalty.

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of finite-lived intangible assets	Intangible assets, net, were as follows (in thousands): June 30, 2020 Gross Amount Accumulated Amortization Net Weighted-Average Amortization Period Developed technology $ 117,380 $ (71,736) $ 45,644 9.9 years Patents and licenses $ 11,274 $ (8,802) $ 2,472 7.8 years December 31, 2019 Gross Amount Accumulated Amortization Net Weighted-Average Amortization Period Developed technology $ 112,000 $ (65,800) $ 46,200 10.0 years Patents and licenses $ 11,274 $ (8,342) $ 2,932 7.8 years
Estimated future intangible asset amortization expense	Based on the carrying value of intangible assets, net, as of June 30, 2020, the amortization expense is expected to be as follows (in thousands): Fiscal Year Developed Technology Amortization Expense Patents and Licenses Amortization Expense Total 2020 (remainder of the year) $ 5,936 $ 457 $ 6,393 2021 11,873 759 12,632 2022 11,873 676 12,549 2023 11,873 570 12,443 2024 2,073 10 2,083 Thereafter 2,016 — 2,016 Total $ 45,644 $ 2,472 $ 48,116

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Summary of cash and cash equivalents	Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Cash and cash equivalents $ 42,965 $ 21,661 Restricted cash 1,075 2,075 Total cash, cash equivalents and restricted cash $ 44,040 $ 23,736
Schedule of restricted cash	Cash, cash equivalents and restricted cash consisted of the following as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Cash and cash equivalents $ 42,965 $ 21,661 Restricted cash 1,075 2,075 Total cash, cash equivalents and restricted cash $ 44,040 $ 23,736
Inventories	Inventories consisted of the following as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Raw materials $ 9,665 $ 6,133 Work-in-process 1,063 659 Finished goods 8,172 7,092 Total inventories $ 18,900 $ 13,884
Property and equipment	Property and equipment consisted of the following as of June 30, 2020 and December 31, 2019 (in thousands): June 30, 2020 December 31, 2019 Computer equipment and software $ 4,376 $ 3,997 Laboratory and manufacturing equipment 19,652 19,325 Leasehold improvements 7,962 7,788 Office furniture and fixtures 2,076 1,824 Property and equipment, gross 34,066 32,934 Less accumulated depreciation and amortization (26,309) (24,954) Construction-in-progress 108 76 Property and equipment, net $ 7,865 $ 8,056
Activity of warranty accrual	Activity for our warranty accrual for the six months ended June 30, 2020 and 2019, which are included in other accrued liabilities, is summarized below (in thousands): Six Months Ended June 30, 2020 2019 Beginning balance $ 1,390 $ 863 Accrual for current period warranties 419 657 Warranty costs incurred (277) (429) Ending balance $ 1,532 $ 1,091

Convertible Notes and Credit _2

Convertible Notes and Credit Facility (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of debt	The carrying values of the components of the 2014 Notes and the 2019 Notes are as follows (in thousands): June 30, 2020 December 31, 2019 2.75% 2014 Notes due 2034 Principal amount $ 1,079 $ 1,079 Unamortized debt discount (24) (18) Unamortized debt issuance cost (4) (4) $ 1,051 $ 1,057 5.25% 2019 Notes due 2024 Principal amount $ 55,000 $ 55,000 Unamortized debt issuance cost (2,038) (2,236) $ 52,962 $ 52,764 Net carrying value of all Notes $ 54,013 $ 53,821 The following table summarizes the par value, carrying value and the estimated fair value of the 2014 and 2019 Notes at June 30, 2020 and December 31, 2019, respectively (in thousands): June 30, 2020 December 31, 2019 Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value 2014 Notes $ 1,079 $ 1,051 $ 1,122 $ 1,079 $ 1,057 $ 1,122 2019 Notes 55,000 52,962 82,369 55,000 52,764 73,975 Total $ 56,079 $ 54,013 $ 83,491 $ 56,079 $ 53,821 $ 75,097

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of balance sheet information	Supplemental balance sheet information related to leases was as follows as of June 30, 2020 and December 31, 2019 (in thousands, except for discount rate and lease term): June 30, 2020 December 31, 2019 Operating lease right-of-use buildings $ 40,618 $ 6,234 Operating lease right-of-use equipment 33 69 Operating lease right-of-use vehicles 452 355 Total operating lease right-of-use assets, gross 41,103 6,658 Accumulated amortization (2,076) (1,798) Total operating lease right-of-use assets, net $ 39,027 $ 4,860 Operating lease liabilities, current $ 2,170 $ 1,833 Operating lease liabilities, non-current 39,139 4,323 Total operating lease liabilities $ 41,309 $ 6,156 Weighted average remaining lease term (in years) 9.1 4.7 Weighted average discount rate per annum 11.9 % 5.0 %
Schedule of lease expense	The following table presents the components of lease expense for the three and six months ended June 30, 2020 and 2019, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost (including variable costs) $ 2,312 $ 1,553 $ 4,511 $ 3,056 Variable costs including non-lease component $ 548 $ 703 $ 1,169 $ 1,303 Supplemental Cash Flow Information: Cash paid for amounts included in the measurement of operating lease liabilities (included in net cash used in operating activities in thousands): Six Months Ended June 30, 2020 2019 Operating cash flows from operating leases $ 1,987 $ 2,061
Schedule of future minimum lease payments	Future minimum lease payments under commenced non-cancelable operating leases, which are as of June 30, 2020 as follows (in thousands): Fiscal Year Minimum Lease Payments for Operating Leases 2020 (remainder of year) $ 3,214 2021 7,282 2022 6,985 2023 6,907 2024 7,120 Thereafter 39,231 Total future minimum payments $ 70,739 Less: imputed interest (29,430) Total $ 41,309

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of cash and available-for-sale securities	The following tables summarize our cash and available-for-sale securities that were measured at fair value by significant investment category within the fair value hierarchy (in thousands): June 30, 2020 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Fair Value Cash and Cash Equivalents Short-Term Marketable Securities Cash- Restricted Assets: Cash-unrestricted $ 20,196 $ — $ — $ 20,196 $ 20,196 $ — $ — Cash-restricted 1,075 — — 1,075 — — 1,075 Total cash $ 21,271 $ — $ — $ 21,271 $ 20,196 $ — $ 1,075 Available-for-sale: Level I: Money market funds $ 22,769 $ — $ — $ 22,769 $ 22,769 $ — $ — US treasury securities 2,428 3 — 2,431 — 2,431 — Subtotal $ 25,197 $ 3 $ — $ 25,200 $ 22,769 $ 2,431 $ — Total $ 46,468 $ 3 $ — $ 46,471 $ 42,965 $ 2,431 $ 1,075 December 31, 2019 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Fair Value Cash and Cash Equivalents Short-Term Marketable Securities Cash- Restricted Assets: Cash-unrestricted $ 16,614 $ — $ — $ 16,614 $ 16,614 $ — $ — Cash-restricted 2,075 — — 2,075 — — 2,075 Total cash $ 18,689 $ — $ — $ 18,689 $ 16,614 $ — $ 2,075 Available-for-sale: Level I: Money market funds $ 5,047 $ — $ — $ 5,047 $ 5,047 $ — $ — US treasury securities 36,942 36 — 36,978 — 36,978 — Subtotal $ 41,989 $ 36 $ — $ 42,025 $ 5,047 $ 36,978 $ — Total $ 60,678 $ 36 $ — $ 60,714 $ 21,661 $ 36,978 $ 2,075
Schedule of debt	The carrying values of the components of the 2014 Notes and the 2019 Notes are as follows (in thousands): June 30, 2020 December 31, 2019 2.75% 2014 Notes due 2034 Principal amount $ 1,079 $ 1,079 Unamortized debt discount (24) (18) Unamortized debt issuance cost (4) (4) $ 1,051 $ 1,057 5.25% 2019 Notes due 2024 Principal amount $ 55,000 $ 55,000 Unamortized debt issuance cost (2,038) (2,236) $ 52,962 $ 52,764 Net carrying value of all Notes $ 54,013 $ 53,821 The following table summarizes the par value, carrying value and the estimated fair value of the 2014 and 2019 Notes at June 30, 2020 and December 31, 2019, respectively (in thousands): June 30, 2020 December 31, 2019 Par Value Carrying Value Fair Value Par Value Carrying Value Fair Value 2014 Notes $ 1,079 $ 1,051 $ 1,122 $ 1,079 $ 1,057 $ 1,122 2019 Notes 55,000 52,962 82,369 55,000 52,764 73,975 Total $ 56,079 $ 54,013 $ 83,491 $ 56,079 $ 53,821 $ 75,097

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of common stock reserved for future issuance	At June 30, 2020, we had reserved shares of common stock for future issuance under equity compensation plans as follows: (in 000's) Securities To Be Issued Upon Exercise Of Options Securities To Be Issued Upon Release Of Restricted Stock and Performance Share Units Number Of Remaining Securities Available For Future Issuance 2009 Equity Incentive Plan 19 — — 2011 Equity Incentive Plan 1,609 6,138 2,823 DVS Sciences Inc. 2010 Equity Incentive Plan 23 — — 2017 Inducement Award Plan 207 241 — 2017 Employee Stock Purchase Plan — — 3,100 1,858 6,379 5,923 Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Restricted Stock Units, Stock Options and Performance Share Units $ 3,331 $ 2,848 $ 5,443 $ 4,993 Employee Stock Purchase Plan 303 144 557 270 Total Share-based Compensation $ 3,634 $ 2,992 $ 6,000 $ 5,263

Stock-Based Plans (Tables)

Stock-Based Plans (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Activity under restricted stock units	Activity under the 2011 Plan, the 2009 Plan, and the Inducement Plan was as follows: Restricted Stock Units : Number of Units (in 000s) Weighted-Average Balance at December 31, 2019 2,551 $ 7.43 RSU granted 3,642 $ 3.95 RSU released (602) $ 7.72 RSU forfeited (222) $ 6.82 Balance as of June 30, 2020 5,369 $ 5.06
Activity under stock options	Stock Options : Number of Weighted-Average Weighted- Aggregate Intrinsic Value (1) in (000s) Balance at December 31, 2019 2,027 $ 7.78 6.8 $ 81 Options granted 105 $ 3.74 Options exercised — $ — Options forfeited (274) $ 5.71 Balance as of June 30, 2020 1,858 $ 7.86 6.1 $ 163 Vested at June 30, 2020 1,372 $ 8.69 5.4 $ 115 Awards expected to vest at June 30, 2020 474 $ 5.50 8.1 $ 48
Schedule of nonvested performance-based units activity	Activity under the TSR-based PSUs is as follows: Number of Units (in 000s) Weighted-Average Balance at December 31, 2019 547 $ 15.09 PSU granted 509 $ 4.82 PSU released — $ — PSU forfeited (94) $ 14.26 Balance at June 30, 2020 962 $ 9.74 Number of Units (in 000s) Weighted-Average Balance at December 31, 2019 64 $ 7.05 PSU granted — $ — PSU released (4) $ 7.05 PSU forfeited (12) $ 7.05 Balance at June 30, 2020 48 $ 7.05
Schedule of stock-based compensation expense	At June 30, 2020, we had reserved shares of common stock for future issuance under equity compensation plans as follows: (in 000's) Securities To Be Issued Upon Exercise Of Options Securities To Be Issued Upon Release Of Restricted Stock and Performance Share Units Number Of Remaining Securities Available For Future Issuance 2009 Equity Incentive Plan 19 — — 2011 Equity Incentive Plan 1,609 6,138 2,823 DVS Sciences Inc. 2010 Equity Incentive Plan 23 — — 2017 Inducement Award Plan 207 241 — 2017 Employee Stock Purchase Plan — — 3,100 1,858 6,379 5,923 Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Restricted Stock Units, Stock Options and Performance Share Units $ 3,331 $ 2,848 $ 5,443 $ 4,993 Employee Stock Purchase Plan 303 144 557 270 Total Share-based Compensation $ 3,634 $ 2,992 $ 6,000 $ 5,263

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) shares in Thousands	1 Months Ended			3 Months Ended					6 Months Ended
	Mar. 31, 2020	Nov. 30, 2019	Feb. 28, 2019	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2018	Mar. 31, 2018	Feb. 28, 2014
Schedule Of Significant Accounting Policies [Line Items]
Total revenue				$ 26,058,000			$ 28,196,000		$ 53,675,000	$ 58,307,000
Legal fees	$ 400,000
Product warranty term									1 year
Impairment of goodwill				0			0		$ 0	0
Loss on extinguishment of debt				0			0		$ 0	9,000,000
Accounting Standards Update [Extensible List]					us-gaap:AccountingStandardsUpdate201613Member				us-gaap:AccountingStandardsUpdate201613Member
Cumulative-effect of new accounting standard for Topic 326 Credit Losses	141,496,000			$ 132,719,000	$ 141,496,000	$ 153,612,000	$ 172,640,000	$ 182,245,000	$ 132,719,000	$ 172,640,000	$ 72,116,000
5 Largest Customers | Revenue from Contract with Customer | Customer Concentration Risk
Schedule Of Significant Accounting Policies [Line Items]
Concentration risk, percentage				32.00%			30.00%		23.00%	20.00%
Cumulative Effect, Period of Adoption, Adjustment
Schedule Of Significant Accounting Policies [Line Items]
Cumulative-effect of new accounting standard for Topic 326 Credit Losses						(100,000)
Commission Costs | Minimum
Schedule Of Significant Accounting Policies [Line Items]
Performance obligation period									1 year
Commission Costs | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Performance obligation period									3 years
Convertible Debt
Schedule Of Significant Accounting Policies [Line Items]
Par Value				$ 56,079,000		56,079,000			$ 56,079,000
Senior Convertible Notes due 2034 | Convertible Debt
Schedule Of Significant Accounting Policies [Line Items]
Par Value				1,079,000		1,079,000			1,079,000				$ 201,300,000
Interest rate on notes												2.75%	2.75%
Debt extinguished		$ 50,200,000
Principal amount		1,100,000		1,079,000		1,079,000			1,079,000			$ 51,300,000
Exchange Convertible Senior Notes due 2034 | Convertible Debt
Schedule Of Significant Accounting Policies [Line Items]
Par Value												$ 150,000,000
Interest rate on notes												2.75%
Loss on extinguishment of debt						3,000,000		$ 9,000,000
Principal amount												$ 150,000,000
Senior Convertible Notes Due 2024 | Convertible Debt
Schedule Of Significant Accounting Policies [Line Items]
Par Value		$ 55,000,000		55,000,000		55,000,000			55,000,000
Interest rate on notes		5.25%
Debt extinguished		$ 51,800,000
Principal amount				55,000,000		55,000,000			55,000,000
Product revenue
Schedule Of Significant Accounting Policies [Line Items]
Total revenue				17,405,000			$ 23,235,000		$ 36,386,000	$ 48,062,000
Product revenue | Minimum
Schedule Of Significant Accounting Policies [Line Items]
Terms of payment period									30 days
Product revenue | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Terms of payment period									60 days
Service revenue
Schedule Of Significant Accounting Policies [Line Items]
Total revenue				5,140,000			4,961,000		$ 10,326,000	10,245,000
Service revenue | Minimum
Schedule Of Significant Accounting Policies [Line Items]
Performance obligation period									1 year
Service revenue | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Performance obligation period									3 years
Other revenue
Schedule Of Significant Accounting Policies [Line Items]
Total revenue	3,100,000			63,000			0		$ 3,163,000	0
Common Stock
Schedule Of Significant Accounting Policies [Line Items]
Conversion of debt into common stock (in shares)								19,460
Cumulative-effect of new accounting standard for Topic 326 Credit Losses	71,000			71,000	71,000	70,000	69,000	$ 69,000	71,000	69,000	49,000
Common Stock | Senior Convertible Notes due 2034 | Convertible Debt
Schedule Of Significant Accounting Policies [Line Items]
Conversion of debt into common stock (in shares)								19,500
Common Stock | Exchange Convertible Senior Notes due 2034 | Convertible Debt
Schedule Of Significant Accounting Policies [Line Items]
Conversion of debt into common stock (in shares)			19,500
Accumulated Deficit
Schedule Of Significant Accounting Policies [Line Items]
Cumulative-effect of new accounting standard for Topic 326 Credit Losses	(639,721,000)			$ (652,736,000)	$ (639,721,000)	(623,641,000)	$ (598,069,000)	$ (584,316,000)	$ (652,736,000)	$ (598,069,000)	$ (558,851,000)
Accumulated Deficit | Cumulative Effect, Period of Adoption, Adjustment
Schedule Of Significant Accounting Policies [Line Items]
Cumulative-effect of new accounting standard for Topic 326 Credit Losses						$ (100,000)
Intellectual Property Infringement Claims
Schedule Of Significant Accounting Policies [Line Items]
Proceeds from legal settlements	$ 3,500,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 141,496	$ 153,612	$ 182,245	$ 72,116	$ 153,612	$ 72,116
Other comprehensive income (loss)	76	(303)	54	10	(227)	64
Ending Balance	132,719	141,496	172,640	182,245	132,719	172,640
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(921)	(618)			(618)
Other comprehensive income (loss)	109	(303)
Ending Balance	(812)	(921)			(812)
Unrealized Gain (Loss) on Investments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	36	36			36
Other comprehensive income (loss)	(33)	0
Ending Balance	3	36			3
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(885)	(582)	(677)	(687)	(582)	(687)
Other comprehensive income (loss)	76	(303)	54	10
Ending Balance	$ (809)	$ (885)	$ (623)	$ (677)	$ (809)	$ (623)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Potential Common Shares Excluded from Computations of Diluted Net Loss Per Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computations of net loss per share (in shares)	29,634	5,457
Stock options, restricted stock units and performance awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computations of net loss per share (in shares)	8,237	4,541
2019 Convertible Notes | Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computations of net loss per share (in shares)	18,966	0
2019 Convertible Notes potential make-whole shares | Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computations of net loss per share (in shares)	2,412	0
2014 Convertible Notes | Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computations of net loss per share (in shares)	19	916

Business Combination - Narrativ

Business Combination - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 17, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Share price (usd per share)	$ 4.22	$ 4.01
Goodwill		$ 106,328		$ 104,108
InstruNor AS
Business Acquisition [Line Items]
Total purchase price	$ 7,214
Purchase price in cash	$ 5,165
Purchase price in shares (shares)	485,451
Goodwill	$ 2,220		$ 2,200

Business Combination - Net Cash

Business Combination - Net Cash Flows (Details) - USD ($) $ in Thousands	Jan. 17, 2020	Jun. 30, 2020	Jun. 30, 2019
Business Acquisition [Line Items]
Acquisition of InstruNor, net of cash acquired		$ 5,154	$ 0
InstruNor AS
Business Acquisition [Line Items]
Purchase price in cash	$ 5,165
Less: cash and cash equivalents acquired	(11)
Acquisition of InstruNor, net of cash acquired	$ 5,154

Business Combination - Schedule

Business Combination - Schedule of Consideration Transferred and Identifiable Assets and Liabilities (Details) - USD ($) $ in Thousands	Jan. 17, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Liabilities assumed:
Goodwill		$ 106,328		$ 104,108
InstruNor AS
Business Acquisition [Line Items]
Cash consideration paid on closing to former equity holders	$ 5,165
Non-cash consideration common shares	2,049
Total purchase price	7,214
Assets acquired:
Cash and cash equivalents	11
Accounts receivable	32
Other receivables	13
Inventories, net	153
Developed technology	5,380
Liabilities assumed:
Accounts payable	14
Other current liabilities	15
Deferred tax liability	566
Fair value of identifiable net assets acquired	4,994
Goodwill	$ 2,220		$ 2,200

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue		$ 26,058	$ 28,196	$ 53,675	$ 58,307
Instruments
Disaggregation of Revenue [Line Items]
Total revenue		8,577	12,201	18,048	25,041
Consumables
Disaggregation of Revenue [Line Items]
Total revenue		8,828	11,034	18,338	23,021
Product revenue
Disaggregation of Revenue [Line Items]
Total revenue		17,405	23,235	36,386	48,062
Service revenue
Disaggregation of Revenue [Line Items]
Total revenue		5,140	4,961	10,326	10,245
Development revenue
Disaggregation of Revenue [Line Items]
Total revenue		3,000	0	3,000	0
License and royalty revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 3,100	63	0	3,163	0
Grant revenue
Disaggregation of Revenue [Line Items]
Total revenue		450	0	800	0
Other revenue
Disaggregation of Revenue [Line Items]
Total revenue		513	0	3,963	0
Americas
Disaggregation of Revenue [Line Items]
Total revenue		13,940	11,120	28,784	24,091
EMEA
Disaggregation of Revenue [Line Items]
Total revenue		6,557	11,217	14,653	19,373
Asia-Pacific
Disaggregation of Revenue [Line Items]
Total revenue		$ 5,561	$ 5,859	$ 10,238	$ 14,843

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Deferred revenue	$ 22.2	$ 20
Revenue recognized	(6.2)
Additional advance payments received	$ 8.4

Revenue - Performance Obligatio

Revenue - Performance Obligations (Details) $ in Thousands	Jun. 30, 2020USD ($)
Revenue from External Customer [Line Items]
Remaining performance obligation	$ 23,903
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
Revenue from External Customer [Line Items]
Remaining performance obligation	$ 7,401
Remaining performance obligation, expected timing of satisfaction	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue from External Customer [Line Items]
Remaining performance obligation	$ 8,636
Remaining performance obligation, expected timing of satisfaction	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue from External Customer [Line Items]
Remaining performance obligation	$ 4,702
Remaining performance obligation, expected timing of satisfaction	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue from External Customer [Line Items]
Remaining performance obligation	$ 3,164
Remaining performance obligation, expected timing of satisfaction

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, net - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Feb. 28, 2014	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jan. 17, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 106,328			$ 106,328			$ 104,108
Amortization of intangibles					5,936	$ 5,600
DVS Sciences, Inc.
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 104,100
InstruNor AS
Finite-Lived Intangible Assets [Line Items]
Goodwill			$ 2,200				$ 2,220
Developed technology
Finite-Lived Intangible Assets [Line Items]
Amortization of intangibles		$ 3,200		$ 3,100	$ 6,400	$ 6,200
Developed technology | DVS Sciences, Inc.
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 112,000
Developed technology | InstruNor AS
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 5,400
Acquired finite-lived intangible assets, useful life			8 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, net - Schedule of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Net	$ 48,116
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Amount	117,380	$ 112,000
Accumulated Amortization	(71,736)	(65,800)
Net	$ 45,644	$ 46,200
Weighted-Average Amortization Period	9 years 10 months 24 days	10 years
Patents and licenses
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 11,274	$ 11,274
Accumulated Amortization	(8,802)	(8,342)
Net	$ 2,472	$ 2,932
Weighted-Average Amortization Period	7 years 9 months 18 days	7 years 9 months 18 days

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, net - Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
2020 (remainder of the year)	$ 6,393
2021	12,632
2022	12,549
2023	12,443
2024	2,083
Thereafter	2,016
Net	48,116
Developed technology
Finite-Lived Intangible Assets [Line Items]
2020 (remainder of the year)	5,936
2021	11,873
2022	11,873
2023	11,873
2024	2,073
Thereafter	2,016
Net	45,644	$ 46,200
Patents and licenses
Finite-Lived Intangible Assets [Line Items]
2020 (remainder of the year)	457
2021	759
2022	676
2023	570
2024	10
Thereafter	0
Net	$ 2,472	$ 2,932

Balance Sheet Details - Summary

Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Cash and cash equivalents	$ 42,965	$ 21,661
Restricted cash	1,075	2,075
Total cash, cash equivalents and restricted cash	44,040	$ 23,736	$ 26,121	$ 95,401
Short-term restricted cash	75
Non-current restricted cash	$ 1,000

Balance Sheet Details - Invento

Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 9,665	$ 6,133
Work-in-process	1,063	659
Finished goods	8,172	7,092
Total inventories	$ 18,900	$ 13,884

Balance Sheet Details - Propert

Balance Sheet Details - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 34,066	$ 32,934
Less accumulated depreciation and amortization	(26,309)	(24,954)
Construction-in-progress	108	76
Property and equipment, net	7,865	8,056
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,376	3,997
Laboratory and manufacturing equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,652	19,325
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,962	7,788
Office furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,076	$ 1,824

Balance Sheet Details - Warrant

Balance Sheet Details - Warranty Accrual (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 1,390	$ 863
Accrual for current period warranties	419	657
Warranty costs incurred	(277)	(429)
Ending balance	$ 1,532	$ 1,091

Convertible Notes and Credit _3

Convertible Notes and Credit Facility - Narrative (Details) $ / shares in Units, shares in Thousands	Apr. 21, 2020USD ($)	Nov. 30, 2019USD ($)$ / sharesRate	Feb. 28, 2019USD ($)shares	Aug. 31, 2018USD ($)	Mar. 31, 2018USD ($)$ / sharesRate	Feb. 28, 2014USD ($)	Jun. 30, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)shares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)	Mar. 12, 2018USD ($)
Debt Instrument [Line Items]
Initial conversion rate of notes | Rate		344.8276%			1.26944%
Common stock, par value (usd per share) | $ / shares							$ 0.001	$ 0.001			$ 0.001
Gain (loss) on extinguishment of debt							$ 0		$ 0		$ 0	$ (9,000,000)
Prepayment fee, percentage	0.25%
Commitment fee amount	$ 112,500			$ 112,500
Convertible Debt
Debt Instrument [Line Items]
Principal amount							56,079,000	$ 56,079,000			56,079,000
Convertible Debt | Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Principal amount						$ 201,300,000	1,079,000	1,079,000			1,079,000
Proceeds from convertible debt issuance						195,200,000
Debt issuance costs						1,100,000	4,000	4,000			4,000
Underwriting discount						$ 6,000,000
Effective interest rate						3.00%
Principal amount		$ 1,100,000			$ 51,300,000		1,079,000	1,079,000			1,079,000
Interest rate on notes					2.75%	2.75%
Proceeds from debt issuance		52,700,000
Debt extinguished		$ 50,200,000
Convertible Debt | Exchange Convertible Senior Notes due 2034
Debt Instrument [Line Items]
Principal amount					$ 150,000,000
Effective interest rate					12.30%
Principal amount					$ 150,000,000
Estimated fair value of debt													$ 145,500,000
Interest rate on notes					2.75%
Initial conversion rate of notes		0.3448276			0.1269438
Common stock, par value (usd per share) | $ / shares					$ 0.001
Initial conversion price of stock (usd per share) | $ / shares		$ 2.90			$ 7.88
Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price					110.00%
Debt and equity offering costs					$ 2,800,000
Offering related costs					2,200,000
Stock issuance costs					$ 600,000
Maximum ability to borrow under line of credit			$ 150,000,000
Gain (loss) on extinguishment of debt								(3,000,000)		$ (9,000,000)
Convertible Debt | Senior Convertible Notes Due 2024
Debt Instrument [Line Items]
Principal amount		$ 55,000,000					55,000,000	55,000,000			55,000,000
Debt issuance costs							2,038,000	2,236,000			2,038,000
Effective interest rate		6.20%
Principal amount							55,000,000	$ 55,000,000			55,000,000
Interest rate on notes		5.25%
Offering related costs		$ 2,300,000
Debt extinguished		$ 51,800,000
Redemption, Period One | Convertible Debt | Exchange Convertible Senior Notes due 2034
Debt Instrument [Line Items]
Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price		150.00%
Redemption, Period Two | Convertible Debt | Exchange Convertible Senior Notes due 2034
Debt Instrument [Line Items]
Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price		130.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount							7,300,000				7,300,000
Maximum ability to borrow under line of credit				$ 15,000,000
Percentage of eligible receivables				85.00%
Percentage of eligible inventory				50.00%
Line of credit outstanding							$ 0				$ 0
Unused revolving line of credit				0.75%
Percentage of interest on obligation upon default											5.00%
Revolving Credit Facility | Minimum | Prime Rate
Debt Instrument [Line Items]
Additional interest rate				0.50%
Revolving Credit Facility | Maximum | Prime Rate
Debt Instrument [Line Items]
Additional interest rate				5.50%
Common Stock
Debt Instrument [Line Items]
Conversion of debt into common stock (in shares) | shares										19,460
Common Stock | Convertible Debt
Debt Instrument [Line Items]
Proceeds from issuance of common stock										$ 133,300,000
Common Stock | Convertible Debt | Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Conversion of debt into common stock (in shares) | shares										19,500
Common Stock | Convertible Debt | Exchange Convertible Senior Notes due 2034
Debt Instrument [Line Items]
Conversion of debt into common stock (in shares) | shares			19,500
Trustee | Convertible Debt | Exchange Convertible Senior Notes due 2034
Debt Instrument [Line Items]
Maximum ability to borrow under line of credit			$ 11,900,000							$ 138,100,000
Gain (loss) on extinguishment of debt			$ (9,000,000)

Convertible Notes and Credit _4

Convertible Notes and Credit Facility - Schedule of Debt (Details) - Convertible Debt - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Nov. 30, 2019	Mar. 31, 2018	Feb. 28, 2014
Debt Instrument [Line Items]
Long-term Debt, Total	$ 54,013	$ 53,821
Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Interest rate on notes				2.75%	2.75%
Principal amount	1,079	1,079	$ 1,100	$ 51,300
Unamortized debt discount	(24)	(18)
Unamortized debt issuance cost	(4)	(4)			$ (1,100)
Long-term Debt, Total	1,051	1,057
Senior Convertible Notes Due 2024
Debt Instrument [Line Items]
Interest rate on notes			5.25%
Principal amount	55,000	55,000
Unamortized debt issuance cost	(2,038)	(2,236)
Long-term Debt, Total	$ 52,962	$ 52,764
Exchange Convertible Senior Notes due 2034
Debt Instrument [Line Items]
Interest rate on notes				2.75%
Principal amount				$ 150,000

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Operating Leased Assets [Line Items]
Renewal term	5 years
Right-of-use asset	$ 39,027		$ 4,860
Reorganized lease liabilities	$ 41,309		$ 6,156
Minimum
Operating Leased Assets [Line Items]
Remaining lease term	1 year
Maximum
Operating Leased Assets [Line Items]
Remaining lease term	10 years
CALIFORNIA
Operating Leased Assets [Line Items]
Right-of-use asset		$ 35,700
Reorganized lease liabilities		$ 35,300
Lease term		10 years
Discount rate		12.55%

Leases - Supplemental Balance s

Leases - Supplemental Balance sheet (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Operating Leased Assets [Line Items]
Gross Amount	$ 41,103	$ 6,658
Accumulated amortization	(2,076)	(1,798)
Total operating lease right-of-use assets, net	39,027	4,860
Operating lease liabilities, current	2,170	1,833
Operating lease liabilities, non-current	39,139	4,323
Total operating lease liabilities	$ 41,309	$ 6,156
Weighted average remaining lease term (in years)	9 years 1 month 6 days	4 years 8 months 12 days
Weighted average discount rate per annum	11.90%	5.00%
Operating lease right-of-use buildings
Operating Leased Assets [Line Items]
Gross Amount	$ 40,618	$ 6,234
Operating lease right-of-use equipment
Operating Leased Assets [Line Items]
Gross Amount	33	69
Operating lease right-of-use vehicles
Operating Leased Assets [Line Items]
Gross Amount	$ 452	$ 355

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease cost (including variable costs)	$ 2,312	$ 1,553	$ 4,511	$ 3,056
Variable costs including non-lease component	$ 548	$ 703	1,169	1,303
Cash paid for amounts included in the measurement of operating lease liabilities (included in net cash used in operating activities in thousands):
Operating cash flows from operating leases			$ 1,987	$ 2,061

Leases - Operating Lease Maturi

Leases - Operating Lease Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Minimum Lease Payments for Operating Leases
2020 (remainder of year)	$ 3,214
2021	7,282
2022	6,985
2023	6,907
2024	7,120
Thereafter	39,231
Total future minimum payments	70,739
Less: imputed interest	(29,430)
Total	$ 41,309	$ 6,156

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Investments and Cash Equivalents (Details) $ in Thousands	Jun. 30, 2020USD ($)investment	Dec. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Fair Value Disclosures [Abstract]
Number of investment in unrealized loss positions | investment	0
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash-unrestricted	$ 42,965	$ 21,661
Cash-restricted	1,075	2,075
Total cash, cash equivalents and restricted cash	44,040	23,736	$ 26,121	$ 95,401
Amortized Cost	46,468	60,678
Gross Unrealized Gain	3	36
Gross Unrealized Loss	0	0
Fair Value	46,471	60,714
Short-Term Marketable Securities	2,431	36,978
Level I
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash-unrestricted	22,769	5,047
Amortized Cost	25,197	41,989
Gross Unrealized Gain	3	36
Gross Unrealized Loss	0	0
Fair Value	25,200	42,025
Short-Term Marketable Securities	2,431	36,978
Money market funds | Level I
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash-unrestricted	22,769	5,047
Amortized Cost	22,769	5,047
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	0
Fair Value	22,769	5,047
Short-Term Marketable Securities	0	0
Long-term Investments	0	0
US treasury securities | Level I
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash-unrestricted	0	0
Amortized Cost	2,428	36,942
Gross Unrealized Gain	3	36
Gross Unrealized Loss	0	0
Fair Value	2,431	36,978
Short-Term Marketable Securities	2,431	36,978
Total cash
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash-unrestricted	20,196	16,614
Cash-restricted	1,075	2,075
Total cash, cash equivalents and restricted cash	21,271	18,689
Cash-unrestricted
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash-unrestricted	20,196	16,614
Cash-restricted
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cash-restricted	$ 1,075	$ 2,075

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Debt (Details) - Convertible Debt - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Nov. 30, 2019	Feb. 28, 2014
Debt Instrument [Line Items]
Par Value	$ 56,079,000	$ 56,079,000
Carrying Value
Debt Instrument [Line Items]
Debt	54,013,000	53,821,000
Fair Value
Debt Instrument [Line Items]
Debt	83,491,000	75,097,000
Senior Convertible Notes due 2034
Debt Instrument [Line Items]
Par Value	1,079,000	1,079,000		$ 201,300,000
Senior Convertible Notes due 2034 | Carrying Value
Debt Instrument [Line Items]
Debt	1,051,000	1,057,000
Senior Convertible Notes due 2034 | Fair Value
Debt Instrument [Line Items]
Debt	1,122,000	1,122,000
Senior Convertible Notes Due 2024
Debt Instrument [Line Items]
Par Value	55,000,000	55,000,000	$ 55,000,000
Senior Convertible Notes Due 2024 | Carrying Value
Debt Instrument [Line Items]
Debt		52,764,000
Senior Convertible Notes Due 2024 | Fair Value
Debt Instrument [Line Items]
Debt	$ 82,369,000	$ 73,975,000

Shareholders' Equity - Narrativ

Shareholders' Equity - Narrative (Details) - USD ($) $ in Thousands	Jan. 17, 2020	Mar. 31, 2019
Convertible Debt | Common Stock
Shareholders' Equity [Line Items]
Shares sold (shares)		19,460,260
Proceeds from issuance of common stock		$ 133,300
InstruNor AS
Shareholders' Equity [Line Items]
Total purchase price	$ 7,214
Purchase price in cash	$ 5,165
Purchase price in shares (shares)	485,451

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Stock Options (Details) shares in Thousands	Jun. 30, 2020shares
Class of Stock [Line Items]
Number Of Remaining Securities Available For Future Issuance (in shares)	5,923
2009 Equity Incentive Plan
Class of Stock [Line Items]
Number Of Remaining Securities Available For Future Issuance (in shares)	0
2011 Equity Incentive Plan
Class of Stock [Line Items]
Number Of Remaining Securities Available For Future Issuance (in shares)	2,823
DVS Sciences Inc. 2010 Equity Incentive Plan
Class of Stock [Line Items]
Number Of Remaining Securities Available For Future Issuance (in shares)	0
2017 Inducement Award Plan
Class of Stock [Line Items]
Number Of Remaining Securities Available For Future Issuance (in shares)	0
2017 Employee Stock Purchase Plan
Class of Stock [Line Items]
Number Of Remaining Securities Available For Future Issuance (in shares)	3,100
Stock Option
Class of Stock [Line Items]
Securities To Be Issued (in shares)	1,858
Stock Option | 2009 Equity Incentive Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	19
Stock Option | 2011 Equity Incentive Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	1,609
Stock Option | DVS Sciences Inc. 2010 Equity Incentive Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	23
Stock Option | 2017 Inducement Award Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	207
Stock Option | 2017 Employee Stock Purchase Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	0
Restricted Stock And Performance Share Units
Class of Stock [Line Items]
Securities To Be Issued (in shares)	6,379
Restricted Stock And Performance Share Units | 2009 Equity Incentive Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	0
Restricted Stock And Performance Share Units | 2011 Equity Incentive Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	6,138
Restricted Stock And Performance Share Units | DVS Sciences Inc. 2010 Equity Incentive Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	0
Restricted Stock And Performance Share Units | 2017 Inducement Award Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	241
Restricted Stock And Performance Share Units | 2017 Employee Stock Purchase Plan
Class of Stock [Line Items]
Securities To Be Issued (in shares)	0

Stock-Based Plans - Narrative (

Stock-Based Plans - Narrative (Details)	Jun. 01, 2020	Jun. 01, 2019USD ($)	May 31, 2019	Jun. 30, 2020USD ($)shares	May 31, 2020numberOfOfferingPeriodsshares	Jun. 30, 2020USD ($)shares	Jun. 30, 2019shares	Jan. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of voting power which impacts the term of equity incentive plan				10.00%		10.00%
ESPP, offering period	6 months	12 months	6 months
Purchase price of common stock, percent	85.00%		85.00%
ESPP, number of six-month offering periods | numberOfOfferingPeriods					2
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period						3 years
Award vesting percentage					50.00%
Number of months over which options vest ratably						36 months
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period						1 year
Award vesting percentage					25.00%
Number of months over which options vest ratably						48 months
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period						4 years
Rate at which outstanding options vest on the first anniversary of the option grant date						25.00%
Awards authorized for issuance (shares) | shares					1,800,000
Total unrecognized compensation cost related to stock-based compensation arrangements				$ 24,800,000		$ 24,800,000
Weighted average remaining contractual terms						3 years
Restricted Stock Units (RSUs) | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Rate at which outstanding options vest on the first anniversary of the option grant date						25.00%
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period						3 years
Total unrecognized compensation cost related to stock-based compensation arrangements				$ 5,700,000		$ 5,700,000
Weighted average remaining contractual terms						2 years
Performance Shares | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of performance period						200.00%
Performance Shares | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of performance period						0.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period						10 years
Stock option grants exercise price minimum percentage on fair market value						100.00%
Stock options held by owners of more than 10% of common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period						5 years
Stock option grants exercise price minimum percentage on fair market value						110.00%
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards authorized for issuance (shares) | shares				1,400,000		1,400,000	5,000,000
2017 Inducement Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards authorized for issuance (shares) | shares								2,000,000
Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to stock-based compensation arrangements				$ 1,400,000		$ 1,400,000
Weighted average remaining contractual terms						1 year 6 months
2017 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional awards authorized for issuance (in shares) | shares				3,000,000
Incremental compensation cost						$ 300,000
2017 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum employee subscription rate		15.00%	10.00%	10.00%		10.00%
Maximum employee purchase amount		$ 25,000

Stock-Based Plans - Restricted

Stock-Based Plans - Restricted and Performance Stock Units (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Restricted Stock Units (RSUs)
Number of Nonvested and Outstanding Units
Beginning Balance (shares) | shares	2,551
Granted (shares) | shares	3,642
Released (shares) | shares	(602)
Forfeited (shares) | shares	(222)
Ending Balance (shares) | shares	5,369
Weighted-Average Grant Date Fair Value per Share
Beginning Balance (usd per share) | $ / shares	$ 7.43
Granted (usd per share) | $ / shares	3.95
Released (usd per share) | $ / shares	7.72
Forfeited (usd per share) | $ / shares	6.82
Ending Balance (usd per share) | $ / shares	$ 5.06
Performance Shares
Number of Nonvested and Outstanding Units
Beginning Balance (shares) | shares	547
Granted (shares) | shares	509
Released (shares) | shares	0
Forfeited (shares) | shares	(94)
Ending Balance (shares) | shares	962
Weighted-Average Grant Date Fair Value per Share
Beginning Balance (usd per share) | $ / shares	$ 15.09
Granted (usd per share) | $ / shares	4.82
Released (usd per share) | $ / shares	0
Forfeited (usd per share) | $ / shares	14.26
Ending Balance (usd per share) | $ / shares	$ 9.74
Certain Employee | Performance Shares
Number of Nonvested and Outstanding Units
Beginning Balance (shares) | shares	64
Granted (shares) | shares	0
Released (shares) | shares	(4)
Forfeited (shares) | shares	(12)
Ending Balance (shares) | shares	48
Weighted-Average Grant Date Fair Value per Share
Beginning Balance (usd per share) | $ / shares	$ 7.05
Granted (usd per share) | $ / shares	0
Released (usd per share) | $ / shares	7.05
Forfeited (usd per share) | $ / shares	7.05
Ending Balance (usd per share) | $ / shares	$ 7.05

Stock-Based Plans - Stock Optio

Stock-Based Plans - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jan. 17, 2020
Number of Options (000s)
Beginning Balance (shares)	2,027
Options granted (shares)	105
Option exercised (shares)	0
Options forfeited (shares)	(274)
Ending Balance (shares)	1,858	2,027
Vested (in shares)	1,372
Unvested awards (shares)	474
Weighted-Average Exercise Price per Option
Beginning Balance (usd per share)	$ 7.78
Options granted (usd per share)	3.74
Options exercised (usd per share)	0
Options forfeited (usd per share)	5.71
Ending Balance (usd per share)	7.86	$ 7.78
Vested (usd per share)	8.69
Unvested awards (usd per share)	$ 5.50
Weighted- Average Remaining Contractual Life
Contractual term	6 years 1 month 6 days	6 years 9 months 18 days
Vested	5 years 4 months 24 days
Unvested awards	8 years 1 month 6 days
Aggregate Intrinsic Value
Outstanding	$ 163	$ 81
Vested	115
Unvested awards	$ 48
Share price (usd per share)	$ 4.01		$ 4.22

Stock-Based Plans - Stock-based

Stock-Based Plans - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Share-based Compensation	$ 3,634	$ 2,992	$ 6,000	$ 5,263
Restricted Stock Units, Stock Options and Performance Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Share-based Compensation	3,331	2,848	5,443	4,993
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Share-based Compensation	$ 303	$ 144	$ 557	$ 270

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ (1,145)	$ (1,143)	$ (1,825)	$ (1,101)

Information About Geographic _2

Information About Geographic Areas (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)segment	Jun. 30, 2019USD ($)
Product Information [Line Items]
Number of reporting segment | segment			1
Sales to customers	$ 26,058	$ 28,196	$ 53,675	$ 58,307
Geographic Concentration Risk | United States | Revenue from Contract with Customer
Product Information [Line Items]
Sales to customers	$ 13,400	$ 9,900	$ 27,500	$ 22,400
Concentration risk, percentage	51.00%	35.00%	51.00%	38.00%
Geographic Concentration Risk | China | Revenue from Contract with Customer
Product Information [Line Items]
Sales to customers	$ 3,500	$ 4,000		$ 7,500
Concentration risk, percentage	13.00%	14.00%		13.00%

Development Agreement (Details)

Development Agreement (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement, up-front and periodic milestone payments, up to	$ 11,700,000		$ 11,700,000
Collaboration agreement, term			1 year
Total revenue	26,058,000	$ 28,196,000	$ 53,675,000	$ 58,307,000
Collaboration agreement, deferred revenue	1,000,000		1,000,000
Development revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	$ 3,000,000	$ 0	$ 3,000,000	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent event	Jul. 31, 2020USD ($)
Subsequent Event [Line Items]
COVID-19 project, budget	$ 37,000,000
COVID-19 project, initial funding	$ 12,200,000